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9General Introduction
1Low BAck PAin: A gLoBAL heALth ProBLeM
Low back pain (LBP) is one of the most common musculoskeletal symptoms (1) as well 
as the leading cause of impaired physical functioning globally (2). In the Western world, 
60 to 90% of all people will experience at least one episode of LBP in their life (3) and, 
at any given point in time, more than half a billion people worldwide experience LBP 
which limits their normal activities (4, 5). In the Netherlands, the incidence of LBP is 80 
per 1000 patient years (6) and the prevalence is 101 per 1000 males and 135.6 per 1000 
females (7); altogether, over 2 million people in Netherlands had spinal pain (back- and 
or neck pain) in the year 2017 (7). Both incidence and prevalence of LBP increase with 
age and the symptom occurs more often in women than in men (6). Half of all people 
with LBP visit their GP because of the pain (3, 8); in 2012, more than 1.5 million people 
sought care for LBP in Dutch general practice (3).
Generally speaking, the natural course of recent onset LBP is favorable: for the major-
ity of patients, pain intensity quickly declines within the first month of follow-up (9). 
However, about a third of patients experience a new episode of LBP within a year (10, 
11) and 19.6% of adults between 20 and 59 years old develop LBP with a duration of 
more than 12 weeks (known as chronic LBP) (12). The largest impact of LBP is related to 
this chronic subtype, because of impairment of physical functioning, which is highest in 
working age groups (2, 4). This in turn leads to productivity loss and work absenteeism, 
with high indirect costs of LBP as a result. In the Netherlands, the total costs associated 
with spinal pain were estimated at 1.3 billion euros in 2011, representing 1.5% of all 
Dutch health expenditures (7). In the United States, these costs were estimated to be 
87.6 billion dollars in 2013 (13).
Specific pathologies of the lumbar spine that may cause LBP include, but are not lim-
ited to, vertebral fractures, axial spondyloarthritis, malignancy and infections (3, 4, 14); 
such causes are found in only a minority of patients presenting with LBP in primary care. 
Up to 90% of patients are labeled as having non-specific LBP (NSLBP), as no specific cause 
for their pain can be found (14-16).
AnALgeSic MedicAtion for Low BAck PAin
Analgesic medicines are ubiquitous in the management of LBP (17, 18). It is estimated 
that 55% of all patients with LBP use analgesics (19); in patients over 55 years of age, this 
percentage was found to be even higher at 72% (20). In the Netherlands in 2012, 985 
LBP-related prescriptions occurred per 1000 LBP patients in general practice (8); this is 
similar to Australia, where 892 analgesics were recommended per 1000 spinal pain prob-
lems managed (21). In a survey in Swiss primary care, the most prescribed medications 
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for LBP were non-steroidal anti-inflammatory drugs (NSAIDs) (97.4% of respondents) and 
paracetamol (94.4%) (17). In 2012, 26% of Dutch LBP patients were prescribed NSAIDs; 
opioids were prescribed to 12% of patients (22). Very likely, this is only “the tip of the 
iceberg”, as over-the-counter medication is also available to patients in many countries.
PArAcetAMoL: the riSe And fALL of A SuPerStAr drug
Worldwide, the most used over-the-counter analgesic is paracetamol (also known as 
acetaminophen) (23, 24). Paracetamol forms the first step of the World Health Orga-
nization (WHO) pain ladder (25) and is widely recommended in many clinical practice 
guidelines for LBP (26). The first clinical results of paracetamol were published in 
1893 by German physician Joseph von Mering (27), who claimed an adverse effect of 
paracetamol was methemoglobinemia (elevated blood levels of methemoglobin which 
may lead to dangerous tissue hypoxia). Because of this severe adverse effect and due to 
the introduction of the popular analgesic aspirin in 1899, paracetamol was essentially 
forgotten for half a century until a series of research articles was published in 1948 by 
British and American scientists, disputing Von Mering’s claims and demonstrating that 
paracetamol could be suitable as an analgesic or antipyretic (28-30). Paracetamol came 
to the market in the 1950s in the United States and the rest is history: today, it is hard 
to imagine a household without paracetamol in the drug cabinet. In the UK, 200 mil-
lion packs were sold over the counter in 2014 (31). Reflecting its wide use, the most 
appropriate unit to measure paracetamol sales may not be the milligram, but the ton 
(31): in the Netherlands, an average of nearly 200 tons of paracetamol is sold every year 
(557.6 tons of paracetamol sold between January 1st 2005 and December 31st 2007) (32). 
Although the working mechanism of paracetamol has long been the subject of debate, 
it is now accepted that the medicine is an inhibitor of the cyclooxygenase (COX) 1 and 
2 enzymes, which effectively belong to the NSAID family (31, 33-35). Paracetamol used 
to be perceived as a harmless drug by both clinicians and patients (23, 36), but globally, 
paracetamol overdose is the number one cause of acute liver failure (37); furthermore, 
a systematic literature review of observational studies has shown that patients taking 
paracetamol also have an increased risk of gastro-intestinal, renal and cardiovascular 
side effects when compared to no paracetamol use (23).
Naturally, the potential benefits of all therapeutic interventions need to be carefully 
balanced with their potential harms; however, this is where a problem has arisen for 
paracetamol (31). Over the last decade, uncertainty has emerged regarding the efficacy 
of paracetamol for several health conditions, including: cancer pain (38), dysmenorrhea 
(39), tension-type headaches (40), migraine (41), post-operative pain (42), and arthritis 
(43, 44). Paracetamol was recommended as the first-choice analgesic for LBP in many 
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1international guidelines (45), until the publication of results from the Paracetamol for 
Acute Low Back Pain (PACE) trial, the first large randomized placebo-controlled trial 
investigating the efficacy of paracetamol for the management of acute NSLBP (46).
The ParaceTamol for acuTe low Back PaIn (Pace) TrIal
The PACE trial was conducted between 2009 and 2013 in Sydney, Australia (46, 47). In 
this randomized controlled trial (RCT), 1652 participants with a new episode of at least 
moderate intensity NSLBP (measured using an adaptation of item 7 of the 36-item Short 
Form Health Survey: “How much bodily pain have you had over the last four weeks?”, 
scored from ‘none’ to ‘very severe’ (48)) were randomly allocated to receive paracetamol 
regularly, paracetamol as-needed or placebo until recovery from LBP or for a maximum 
of four weeks, whichever occurred first (46, 47). In the original trial analyses, there was 
neither a statistically significant nor a clinically relevant difference between paracetamol 
(whether taken regularly or as-needed for pain) and placebo for time until recovery from 
LBP, LBP intensity, physical functioning, health-related quality of life (HRQoL) and sleep 
quality (46). Based on this trial, a 2016 Cochrane systematic review concluded that there 
is high-quality evidence for no difference between paracetamol and placebo for pain 
relief and improvement of physical functioning at the immediate and short term follow-
up (49).
Despite the fact that the PACE trial demonstrated that paracetamol had no effect on 
the outcomes of LBP as compared to placebo, it is still recommended for the treatment 
of acute LBP in Dutch general practice (3). Over the years, many countries have published 
clinical practice guidelines for the treatment of NSLBP in order to rationalize the orga-
nization and delivery of health care and to optimize treatment outcomes on a societal 
level (26, 45); the first of these guidelines was already published in 1987 (50). Although 
these guidelines share one body of evidence, differences may exist between the way 
this evidence is interpreted by policymakers in different countries. This leads to the first 
research question of this thesis:
1. what are the similarities and differences between recommendations for pharma-
cotherapy of nSlBP from recent national clinical practice guidelines, and how do 
these recommendations compare to the best available evidence?
Since the PACE trial is the first and only high-quality RCT that investigated the efficacy 
of paracetamol for acute NSLBP, evidence from this study is highly influential on clini-
cians and policymakers. Therefore, the reproducibility of the PACE results remains highly 
important, as early acceptance of results that cannot be reproduced, may lead to harms 
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in pati ents (51). Although reproducibility is one of the cornerstones of scienti fi c research 
(52, 53), it is oft en an excepti on rather than a rule in clinical research. In recent years, 
reproducibility (or lack thereof) has att racted att enti on in psychology (54), basic science 
(55) and cancer research (56, 57). Following the ‘new lexicon for research reproduc-
ibility’ that was published by Goodman and colleagues in 2016, there are three types of 
reproducibility: methods reproducibility, results reproducibility and inferenti al reproduc-
ibility (58-60). A graphical representati on of these diff erent types of reproducibility is 
presented in Figure 1. In methods reproducibility, an analysis is reproduced using the 
same data, analysis plan and stati sti cal code; the only diff erence is the data analyst (58-
60). Results reproducibility refers to the collecti on of new data in the same populati on, 
followed by analysis using the same analysis plan (58-60); this type of reproducibility 
Population
Research question
Study design
Data
Analysis plan
Statistical code
Data analyst
Estimates
Scientific claims
A B C D
figure 1: Diff erent types of reproducibility in research according to Goodman’s lexicon (58). Column A 
represents an original study. Columns B, C and D represent reproducti on studies, with changes as com-
pared to the original study represented in grey. Column A represents a methods reproducti on study. 
Column B represents a results reproducti on study (also known as a replicati on study). Column D rep-
resents an inferenti al reproducti on study. Figure adapted from Pati l and colleagues, BioRxiV 2017 (59). 
Icons made by Daniel Bruce, Eucalyp, Freepik and Smashicon from www.ﬂ ati con.com.
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1is also called ‘replication’. Inferential reproducibility is defined as the making of new 
knowledge claims of similar strength from either a new data collection or a reanalysis 
of original data (58-60). In the PACE trial, methods reproduction was already performed 
(46), but results reproducibility and inferential reproducibility are important research 
priorities before paracetamol is completely dismissed as a treatment for acute LBP. This 
yields the following research questions related to reproducibility:
2. can the results of the Pace trial be reproduced in Dutch general practice?
3. can the causal inferences made in the PAce trial be reproduced in an independent 
reanalysis of the original data?
Apart from uncertainty regarding the reproducibility of the results of PACE, the conclu-
sions of the PACE trial have been also been challenged stating non-compliance to treat-
ment could have played a role in the results (61, 62). However, assessing the efficacy of 
an intervention in participants who comply with treatment is difficult using conventional 
statistical analysis techniques. In complier average causal effects (CACE) analysis, treat-
ment compliers are compared to participants from the control group who, had they been 
randomized to the treatment group, would have complied to the intervention as well 
(so-called would-be compliers) (63-65). This analysis technique has been demonstrated 
to produce unbiased estimates for the treatment effect in compliers (65). This leads to 
the fourth research question:
4. what is the efficacy of paracetamol for acute nSlBP in participants of the Pace 
trial who complied with the treatment regimen?
It is already known that treatment outcomes in people with acute LBP are influenced by 
patient expectations and beliefs (66). Similarly, reporting adverse events (AEs) in PACE 
could be associated with reporting worse outcomes of LBP. This leads to the fifth and 
final research question of this thesis:
5. Is there an association between reporting aes and the outcomes of acute lBP in 
the Pace trial?
the AiM And outLine of thiS theSiS
This thesis aims to strengthen the evidence about the efficacy of paracetamol for acute 
LBP in general practice. In order to answer the five research questions stated above, six 
research projects were conducted.
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To investigate the similarities and differences between recommendations for phar-
macotherapy of NSLBP from recent national clinical practice guidelines, a systematic 
literature review was conducted. In chapter 2, an overview of recent clinical practice 
guidelines is presented and compared to the best available evidence regarding the ef-
ficacy of pharmacological treatments.
A new RCT to follow-up on the PACE trial (called the PACE Plus trial) was designed to 
assess if the results of PACE could be reproduced in Dutch general practice; an additional 
aim of this study was to compare the efficacy of paracetamol to that of diclofenac (an 
NSAID) and advice only. In chapter 3, the study protocol of the PACE Plus trial is pre-
sented. The reality of doing research is that many projects take longer than expected, 
or are even cancelled completely because of feasibility issues (67). Unfortunately, this 
was also the case for the PACE Plus trial. Of course, there’s only one thing more pain-
ful than learning from experience, and that is not learning from experience (Archibald 
Macleish, American poet). The discontinuation of the PACE Plus trial has therefore been 
transparently communicated, in the hope that future researchers in this field may avoid 
the problems that were encountered in this RCT. The results of this communication can 
be found in chapter 4.
Three secondary analyses of original data collected in the PACE trial were conducted. 
To begin with, the first independent inferential reproduction analysis in the field of LBP 
research was conducted to investigate if the causal inferences made in the PACE trial 
were reproducible; the original researchers of the PACE trial had no influence on the 
aim, methods and conclusions. The results of this study are presented in chapter 5. 
Second, the efficacy of paracetamol for acute LBP in participants who complied with the 
treatment regimen was investigated in chapter 6, using a CACE analysis. Finally, the as-
sociation between reporting AEs in PACE and outcomes of LBP was assessed in chapter 7.
In chapter 8, the most important findings of this thesis are summarized and the 
strengths and weaknesses are discussed. Furthermore, these findings are put in context 
of the current medical literature and finally, implications for clinical practice and unan-
swered questions for future research are debated.
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ABStrAct
Introduction
Analgesic drugs are often prescribed to patients with low back pain (LBP). Recommenda-
tions for non-invasive pharmacological management of LBP from recent clinical practice 
guidelines were compared with each other and with the best available evidence on drug 
efficacy.
Methods
Guideline recommendations concerning opioids, non-steroidal anti-inflammatory drugs 
(NSAIDs), paracetamol, antidepressants, anticonvulsants and muscle relaxants from 
national primary care guidelines published within the last 3 years were included in this 
review. For each pharmacotherapy, the most recent systematic review was included as 
the best available evidence on drug efficacy and common adverse effects were sum-
marized.
results
Eight recent national clinical practice guidelines were included in this review (from 
Australia, Belgium, Canada, Denmark, The Netherlands, UK and US). Guidelines are 
universally moving away from pharmacotherapy due to the limited efficacy and the risk 
of adverse effects. NSAIDs have replaced paracetamol as the first choice analgesics for 
LBP in many guidelines. Opioids are considered to be a last resort in all guidelines, but 
prescriptions of these medications have been increasing over recent years. Only limited 
evidence exists for the efficacy of antidepressants and anticonvulsants in chronic LBP. 
Muscle relaxants are one of the analgesics of first choice in the US, but aren’t widely 
available and thus not widely recommended in most other countries.
conclusions
Upcoming guideline updates should shift their focus from pain to function and from 
pharmacotherapy to non-pharmacologic treatment options.
23
Guideline recommendations for pharmacotherapy
2
introduction
Low back pain (LBP) is one of the most prevalent musculoskeletal symptoms and the 
number one cause of disability worldwide (1, 2). Research into the natural course of LBP 
in the general population demonstrated that recent onset LBP often improves rapidly 
during the first 2 months of follow up (3). However, the one-year risk of recurrence is 
estimated to be around 33% (2, 4, 5). Furthermore, 19.6% of all adults between 20 and 
59 develop chronic LBP (i.e. LBP with a duration of more than 12 weeks), which is respon-
sible for a high burden due to disability as well as high cost due to direct medical costs, 
and indirect costs due to work absenteeism and loss of productivity (6). In up to 99% 
of patients presenting with LBP in primary care, no specific nociceptive source for their 
complaints is found. These patients are often labeled as having non-specific LBP (NSLBP), 
which is essentially a basket term for LBP without a known cause (7, 8).
Many LBP patients use analgesics for symptom relief (9). Over recent years, there has 
been an increase in the prescription of opioids, antidepressants and anticonvulsants for 
back pain in primary care (10). Estimates of analgesic usage in LBP range from 55% (11) to 
72% in elderly patients (age >55 years) (12). A recent Australian study reported analgesics 
were recommended at a rate of 892.2 per 1000 spinal pain problems managed between 
2013 and 2014 (10). Findings from this study showed that the noninvasive pharmacologi-
cal options that were most often prescribed in primary care were (in order of descending 
recommendation rate per 1000 spinal problems managed between 2013 and 2014): 
opioids (277.2 recommendations), non-steroidal anti-inflammatory drugs (NSAIDs; 
165.9 recommendations), simple analgesics such as paracetamol (acetaminophen; 137.2 
recommendations), antidepressants and anticonvulsants (76.2 recommendations) and 
muscle relaxants (<106.1 recommendations, in the category ‘other medicine group’) 
(10). Invasive pharmacological options for the treatment of LBP include epidural, spinal, 
facet joint or sacroiliac analgesic or corticosteroid injections; however, these therapies 
are not commonly used in primary care and will therefore not be discussed in this review.
In order to rationalize care, many countries have developed and issued clinical practice 
guidelines containing recommendations for the diagnosis and treatment of LBP (including 
tools for the recognition of specific causes of LBP and recommendations for the manage-
ment of NSLBP) (13); the first of these guidelines was published in 1987 by the Quebec 
Task Force on Spinal Disorders (14). During recent years, many national guidelines for the 
management of LBP in primary care have been updated. The main aims of this review are 
twofold: first, to compare the recommendations for pharmacological treatment of NSLBP in 
primary care between recently published national guidelines and second, to compare these 
guideline recommendations with best available evidence regarding the efficacy of pharma-
cological treatments. A secondary aim of this review is to summarize the most common 
adverse effects (AEs) of noninvasive pharmacological treatments in NSLBP in primary care.
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MethodS
This review focuses on recent clinical practice guidelines for the management of NSLBP 
in primary care and recent (Cochrane) systematic reviews and meta-analyses of random-
ized controlled trials (RCTs) about noninvasive pharmacological treatment of NSLBP. The 
search for clinical guidelines was conducted using the following databases: PubMed 
(key words: low back pain, clinical guidelines), National Guideline Clearinghouse (www.
guideline.gov, keyword: low back pain), National Institute for Health and Care Excellence 
(NICE) (www.nice.org.uk, key word: low back pain) and Physiotherapy Evidence Database 
(PEDro) (key words: low back pain, guideline). Furthermore, the contents and reference 
lists of reviews of guidelines were hand searched. Clinical practice guidelines had to meet 
the following inclusion criteria: (1) the main topic of the guideline was the management 
of LBP (recommendations regarding the management of sciatica will not be considered), 
(2) the guideline concerns the primary care setting, (3) the guideline provides recom-
mendations for pharmacotherapy in NSLBP, and (4) the guideline was written in English, 
German or Dutch as these languages could be read by the reviewers. Guidelines pub-
lished before January 1st 2016 were not considered to be recent and were excluded from 
this review. One guideline was included per country. Clinical practice guidelines from the 
following countries and agencies were included in this review:
- Australia, New South Wales Agency for Clinical Innovation (2016) (15)
- Belgium, Belgian Health Care Knowledge Centre (KCE) (2017) (16)
- Canada, Institute of Health Economics (IHE) (2017) (17)
- Denmark, Danish Health Authority (DHA) (2018) (18)
- Germany, German Association for Quality Assurance in Medicine (ÄZQ) (2017) (19)
- The Netherlands, Dutch College of General Practitioners (NHG) (2017) (20)
- United Kingdom (UK), NICE (2017) (21)
- United States (US), American College of Physicians (ACP) (2017) (22)
efficacy of pharmacological treatments
Based on the recent study by Mathieson et al (10), we identified the following six 
pharmacological treatments of NSLBP (in order of descending recommendation rate per 
1000 spinal problems managed between 2013 and 2014): (1) opioids, (2) NSAIDs, (3) 
paracetamol, (4) antidepressants, (5) anticonvulsants and (6) muscle relaxants. To obtain 
evidence regarding the efficacy of these treatments, we started by hand-searching the 
reviews of the Cochrane Back and Neck Group (back.cochrane.org) for all Cochrane re-
views and meta-analyses concerning these pharmacological treatments published until 
May 2018. Six Cochrane reviews and meta-analyses were found in this search (23-28).
An additional search for systematic reviews and meta-analyses published since the 
above Cochrane reviews was performed in Medline Ovid, PubMed and Embase. Key-
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words used for the searches were low back pain and name of the pharmacotherapy, e.g. 
“low back pain” AND paracetamol. For each pharmacological treatment, the most recent 
review was selected. Six additional studies were found during this search (29-34).
Next, we determined which articles would be used as best available evidence. For each 
of the five pharmacological treatments, we chose the most recent review available. For 
the final selection of systematic reviews, see Box 1.
MS and CL independently scored the quality of the all reviews included for efficacy of 
the five pharmacological treatments based on the additional search using the AMSTAR 2 
tool, a validated critical appraisal tool for systematic reviews (35). This checklist consists 
of 16 questions that can be answered with Yes, Partial Yes, No or Other. Systematic 
reviews scoring at least 8 out of 16 items with ‘Yes’ were considered to have adequate 
quality for inclusion; systematic reviews scoring 7 or less out of 16 were excluded from 
the review and replaced by an older available systematic review on the same pharmaco-
logical treatment. A consensus meeting was held to discuss articles about which there 
was disagreement between the reviewers. In case a consensus could not be reached, a 
third independent reviewer (BK) made the final decision whether or not to include the 
article into the review.
In order to summarize the most common AEs of noninvasive pharmacological treat-
ments for NSLBP in primary care, we searched for evidence about safety and AEs 
(observational studies and systematic reviews) in Medline Ovid, PubMed and Embase. 
Keywords used for the searches were combinations of the name of the pharmacotherapy 
and the extra keywords “safe” or “adverse”, e.g. paracetamol AND safe* OR adverse.
Quality of evidence
All included systematic reviews in Box 1 scored at least 8 out of 16 questions of the 
AMSTAR 2 tool with ‘Yes’ and were thus considered to have adequate quality for inclu-
sion in this review.
Box 1: Final selection of systematic reviews
Opioids Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic 
review and meta-analysis (2016) (29).
NSAIDs Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis (2017) 
(34).
Paracetamol Paracetamol for low back pain (2016) (26).
Antidepressants Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College 
of Physicians Clinical Practice Guideline (2017) (30).
Anticonvulsants Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-
analysis of randomized controlled trials (2017) (31).
Muscle relaxants Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis 
(2017) (32).
NSAIDs: Non-Steroidal Anti-Inflammatory Drugs; NSLBP: Non-Specific Low Back Pain.
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reSuLtS
Pharmacotherapy recommendations in guidelines
Eight recent national clinical practice guidelines were included in this review (from Aus-
tralia, Belgium, Canada, Denmark, Germany, The Netherlands, UK and US). Recommen-
dations for each of the pharmacological treatments are summarized in tables (Table 1-6); 
each pharmacological treatment is discussed separately below in order of descending 
recommendation rate per 1000 spinal problems managed between 2013 and 2014 (10), 
preceded by a general section describing the recommendations of the different national 
guidelines regarding commencement of pharmacotherapy in NSLBP.
recommendations regarding the initiation of pharmacotherapy for nSlBP in 
primary care
Variations exist between clinical practice guidelines on when to consider commencing 
pharmacological management for LBP in primary care. Five guidelines (Australia, Bel-
gium, Canada, The Netherlands and the UK) present pharmacotherapy as a treatment 
option that may be considered if required by the patient. Both the Dutch and German 
guideline specifically mention that analgesics are only used to support patients to return 
to their usual activities.
The guidelines from Denmark and the US are more hesitant in recommending the pre-
scription of analgesics to patients with LBP: the Danish guideline states that physicians 
should only prescribe pain medication after careful consideration, while the American 
guideline specifically recommends selecting non-pharmacological treatment with 
superficial heat, massage, acupuncture or spinal manipulation over pharmacological 
treatment options.
Guideline recommendations and best available evidence regarding opioids
An overview of guideline recommendations related to opioids for NSLBP is presented in 
Table 1. Guidelines universally recommend avoiding opioids, specifically stating that the 
prescription of opioids should only be considered in case other treatment options have 
been contra-indicated, have not been tolerated or have failed to reduce pain. The Cana-
dian and German guidelines mention reassessment of patients to whom opioids have 
been prescribed; the latter mentions this should happen with intervals no longer than 
four weeks. Duration of opioid treatment in acute LBP was mentioned in two guidelines 
(Canada and The Netherlands); The Canadian guideline reports a period of less than one 
or two weeks while the Dutch guideline reports a maximum of five days. The Belgian 
guideline states no specific period but instead mentions opioids should be used for acute 
LBP for the shortest period possible.
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table 1: Guideline recommendations concerning opioids for non-specific low back pain
Guideline Recommendations
Australia (2016) -
Belgium (2017) •  Think about weak opioids (with or without paracetamol) for the shortest period 
possible for managing acute low back pain with or without radicular pain only if 
an NSAID is contraindicated, not tolerated or has been ineffective.
•  Do not routinely offer opioids for managing chronic low back pain with or 
without radicular pain.
Canada (2017) •  Cautious and responsible use of opioids should only be considered for carefully 
selected patients with severe acute pain not controlled with acetaminophen 
and NSAIDs, at a minimum effective dose only for a limited period of time, 
usually less than one to two weeks.
•  Ongoing need for opioids is an indication for reassessment.
•  Evidence is lacking for long-term use of opioids for chronic low back pain. 
However, there is some evidence of the benefit of opioids for short-term pain 
and function improvements.
•  Long-term use of opioids should only follow an unsuccessful trial of non-opioid 
analgesics. In severe chronic pain, strong opioids require careful consideration.
•  Long-acting opioids are preferred as they can establish a steady state blood 
and tissue level that may minimize the patient’s experience of unsteady dosing 
(cyclical improvement and/or withdrawal) from short-acting opioids. Any use of 
opioids over the long term will lead to physical dependence.
•  Avoid escalating doses above 50 mg/day if initiating, and above 90 mg/day oral 
morphine equivalent for ongoing use.
•  Careful attention to incremental improvements in pain or function is required 
to justify ongoing use of opioids. Because little is known about the long-term 
effects of therapy it should be monitored carefully.
•  A history of addiction is a relative contraindication. Consultation with an 
addictions specialist may be helpful in these cases.
Denmark (2018) •  Do only offer patients with recent onset LBP opioids in addition to usual care 
after careful consideration, as the evidence points towards no short-term effect.
Germany (2017) •  Opioid drugs can be a treatment option for acute non-specific low back pain if 
non-opioid analgesics are contraindicated or have been found to be ineffective 
in the individual patient.
•  The indication for opioid drugs should be regularly reassessed at intervals of no 
longer than 4 weeks.
•  [opioids] can be used to treat chronic non-specific low back pain for 4 to 12 
weeks initially.
•  If this brief period of treatment brings about a relevant improvement in the 
patient’s pain and/or subjective physical impairment, while causing only minor 
or no side effects, then opioid drugs can also be a long-term therapeutic option.
The Netherlands 
(2017)
•  Prescribe opioids only to patients with severe acute low back pain, for whom 
weaker analgesics were ineffective. Inform patients about the side-effects of 
opioids and minimize duration of treatment, to a maximum of five days.
•  Prescribe opioids only to patients with chronic non-specific low back pain who 
experience severe disability, in order to support stepwise increase of activity. 
Minimize duration of treatment, to a maximum of one to two weeks.
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For chronic LBP, recommendations concerning opioid prescription are presented with 
hesitation in nearly all guidelines. The British guideline recommends not prescribing opi-
oids at all for patients with chronic LBP, while the Belgian, Canadian, Dutch and American 
guidelines advise caution but are generally less strict. The German guideline recom-
mends the use of opioids for the treatment of chronic LBP. The guideline from Canada 
has by far the most comprehensive recommendations: even the use of long-acting versus 
short-acting opioids and specific doses for oral morphine are mentioned. Furthermore, 
this is the only guideline specifically discussing addiction in its recommendations. The 
Australian guideline only states that opiates are usually less effective for neuropathic 
pain than other analgesics; for this reason, no recommendation on the prescription of 
opioids was included in this review.
Duration of opioid treatment in chronic LBP was mentioned in two guidelines (Ger-
many and The Netherlands); the Dutch guideline limits the use of opioids to a maximum 
of one to two weeks, while the German guideline suggests an initial treatment period 
of four to 12 weeks, stating that opioid treatment may be continued in the long term if 
patients experience a relevant improvement in pain or impairments and have only minor 
or no AEs. The guideline from Denmark only concerns acute LBP and thus presents no 
recommendations for the use of opioids in chronic LBP.
table 1: Guideline recommendations concerning opioids for non-specific low back pain (continued)
Guideline Recommendations
UK (2017) •  Do not routinely offer opioids for managing acute low back pain.
•  Consider weak opioids (with or without paracetamol) for managing acute 
low back pain only if an NSAID is contraindicated, not tolerated or has been 
ineffective.
•  Do not offer opioids for managing chronic low back pain.
US (2017) •  Opioids should be the last treatment option considered and should be 
considered only in patients for whom other therapies have failed because they 
are associated with substantial harms.
Best available 
evidence
Main findings
Efficacy, Tolerability, 
and Dose-Dependent 
Effects of Opioid 
Analgesics for 
Low Back Pain: A 
Systematic Review 
and Meta-analysis. 
(2016)
•  For people with chronic low back pain who tolerate the medicine, opioid 
analgesics provide modest short-term pain relief but the effect is not likely to be 
clinically important within guideline recommended doses.
•  Evidence on long-term efficacy is lacking.
•  The efficacy of opioid analgesics in acute low back pain is unknown.
LBP: low back pain; mg: milligrams; NSAID: non-steroidal anti-inflammatory drug; UK: United Kingdom; 
US; United States of America.
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The 2016 review about opioids for both acute and chronic LBP was considered to be 
the best available evidence (29). For acute LBP, the efficacy of analgesics remains un-
known, as no placebo-controlled trials enrolled patients with acute LBP (29). The review 
presented moderate-quality evidence that opioids have a small short-term effect on pain 
(mean difference of 10.1 points on a 100-point pain scale, 95% Confidence Interval (CI) 
7.4-12.8 points) (29); however, the authors reported large numbers of patients with-
drawing from trials because of AEs or lack of efficacy (29). No trials investigated long 
term effects (29).
Apart from the aforementioned drug dependence, common AEs of opioids are nausea, 
dizziness, constipation, vomiting, somnolence, dry mouth and an increased risk of falling 
and fractures; the risk ratio of experiencing any AE in short term opioid use was found 
to be 1.4 when compared to placebo (36-38). Furthermore, patients who use opioids 
for a longer period of time may experience depression and sexual dysfunction (38); 
meanwhile, patients attempting to stop taking opioids after prolonged use may develop 
a withdrawal syndrome (with symptoms including agitation, insomnia, diarrhea, rhinor-
rhea, piloerection and hyperalgesia) (38). Risks of misuse (estimated rates 21-29%, 95% 
CI 13-38%) and of developing drug-dependence (estimated rates 8-12%, 95% CI 3-17%) 
have been demonstrated in patients with chronic non-cancer pain (such as LBP) (39).
Guideline recommendations and best available evidence regarding non-steroidal 
anti-inflammatory drugs (nSaIDs)
An overview of guideline recommendations related to NSAIDs for NSLBP is presented in 
Table 2. All guidelines recommend NSAIDs for acute LBP; for the guidelines that recom-
mended against the use of paracetamol, NSAIDs are the analgesic of first choice except in 
the US, where physicians are advised to choose between NSAIDs and skeletal muscle re-
laxants (SMRs) based on patient preferences and risk profiles. The Danish guideline is the 
only guideline stating that no effect on LBP is expected of NSAIDs; in the Dutch guideline, 
it is stated that NSAIDs are not expected to be more effective than paracetamol for LBP.
Cyclo-oxygenase 2 inhibitors (COX-2-inhibitors) are mentioned in the Australian, 
Canadian, German and American guidelines. The Australian and German guidelines 
recommend considering contra-indications of COX-2-inhibitors when prescribing them. 
The guideline from the US does not make a recommendation about prescribing COX-2-
inhibitors, as they were not assessed for their effect on pain or function. The Canadian 
guideline only mentions COX-2-inhibitors in the context of the prescription of proton 
pump inhibitors (PPIs) to those using NSAIDs over 45 years of age.
Only the Canadian and American guidelines specifically mention chronic LBP. The 
guideline from Canada recommends paracetamol and NSAIDs for both acute and chronic 
LBP. The guideline from the US states that in patients with chronic LBP, NSAIDs had a 
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small to moderate effect on pain and no effect on function, but should be the first option 
considered nonetheless.
A 2017 review on the effects of NSAIDs for LBP and neck pain (together referred to as 
‘spinal pain’) concluded that although NSAIDs are effective for pain reduction when com-
pared to placebo, differences between NSAIDs and placebo were not clinically relevant 
(34). In acute LBP, NSAIDs were associated with small improvements in pain intensity 
within 2 weeks (immediate term) when compared to placebo (mean difference 6.4 points 
on a 100-point pain scale, 95% CI 2.5 – 10.3 points); furthermore, the short term effects 
of NSAIDs on pain (follow-up duration 2 weeks to 3 months) were non-significant when 
compared to placebo (mean difference 1 point on a 100-point pain scale, 95% CI -3.9 – 
5.9 points). In chronic LBP, NSAIDs were associated with significant results on pain relief 
when compared to placebo at both the immediate term (mean difference 11.1 points 
on a 100-point pain scale, 95% CI 8.4 – 13.8 points) and short term (mean difference 9.8 
points on a 100-point pain scale, 95% CI 7.0 – 12.7 points)(34).
For disability, this review found NSAIDs had a significant effect on disability when com-
pared to placebo in patients with acute LBP at the immediate term (mean difference 7.1 
points on a 100-point disability scale, 95% CI 1.9 – 12.4 points) but no difference at the 
short term (mean difference 0.4 on a 100-point disability scale, 95% CI -4.5 – 5.4 points). 
In chronic LBP, NSAIDs were associated with small but significant differences in disabil-
ity when compared to placebo at both the immediate term (mean difference 8.4 on a 
100-point disability scale, 95% CI 6.3 – 10.6 points) and the short term (mean difference 
7.9 on a 100-point disability scale, 95% CI 4.0 – 11.8 points)(34). Furthermore, the risk 
of gastro-intestinal AEs was reported to have increased 2.5 times (risk ratio; 95% CI 1.2 – 
5.2) for those using NSAIDs when compared to placebo; however, observational studies 
rather than randomized trials are suited to study the prevalence of AEs of medication.
Use of all NSAIDs (both conventional and COX-2-inhibitors) leads to an increased risk of 
cardiovascular disorders (such as myocardial infarction, cerebrovascular events and heart 
failure; increase in overall cardiovascular risk of 35-40% for all NSAIDs except naproxen 
when compared to placebo) (37, 40, 41). Gastro-intestinal AEs are also common (41), 
but may be avoided by simultaneously prescribing PPIs (42). All but the Danish guidelines 
directly alert their readers to the risk of AEs when using NSAIDs. The four guidelines that 
recommend NSAIDs as first choice analgesic (Belgium, Germany, UK and US) all state that 
NSAIDs should be prescribed in the lowest effective dose and for the shortest possible 
period of time. The Canadian guideline is the only document that recommends the use 
of PPIs to all patients over 45 years of age using NSAIDs. Only the guideline from The 
Netherlands mentions dermal NSAIDs as an alternative to oral NSAIDs in order to avoid 
systemic AEs.
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table 2: Guideline recommendations concerning NSAIDs for non-specific low back pain
Guideline Recommendations
Australia (2016) •  NSAIDs are recommended for reducing pain for short periods. However, 
assessment for contraindications is required before prescribing NSAIDs. These 
include severe hypertension, renal disease, previous gastrointestinal haemorrhage 
and current corticosteroid use. The lower incidence of gastrointestinal side effects 
must be balanced with increased cardiovascular risks associated with some CoX-2 
NSAIDs (Cyclo-oxygenase 2 inhibitors are anti-inflammatory medications that have 
lower gastrointestinal side effects when compared to other NSAIDs).
Belgium (2017) •  If a medication is required for managing low back pain with or without radicular 
pain (e.g. due to severity of the pain and patients’ preferences), consider 
oral NSAIDs taking into account potential differences between NSAIDs in 
gastrointestinal, liver and cardio-renal toxicity and the person’s risk factors, 
including age.
•  When prescribing oral NSAIDs for low back pain, think about appropriate clinical 
assessment, ongoing monitoring of the evolution of risk factors, and the use of 
gastro protective treatment.
•  When prescribing oral NSAIDs for low back pain, select the lowest effective dose 
for the shortest possible period of time.
Canada (2017) •  Acute low back pain: Prescribe medication, if necessary, for pain relief preferably to 
be taken at regular intervals. First choice acetaminophen; second choice NSAIDs.
•  Chronic low back pain: Recommend acetaminophen and NSAIDs.
•  A proton pump inhibitor (PPI) should be considered for patients over 45 years of 
age when using an oral NSAID/COX-2 inhibitor.
Denmark (2018) •  Do only offer patients with recent onset LBP NSAIDs in addition to usual care after 
careful consideration, as the evidence points towards no short-term effect
Germany (2017) •  To minimize side effects NSAIDs should be given in the lowest effective dose and 
for the shortest possible time.
•  Considering the contraindications, COX-2-inhibitors can be used if NSAIDs are 
contraindicated or poorly tolerated (off-label-use).
The Netherlands 
(2017)
•  NSAIDs are not expected to be more effective than paracetamol for low back pain.
•  Dermal NSAIDs may be considered as an alternative to oral NSAIDs. Dermal NSAIDs 
have fewer systemic side-effects and may therefore be also used in elderly people 
with reduced renal function or heart failure (given their skin is intact).
UK (2017) •  Consider oral non-steroidal anti-inflammatory drugs (NSAIDs) for managing low 
back pain, taking into account potential differences in gastrointestinal, liver and 
cardio-renal toxicity, and the person’s risk factors, including age.
•  When prescribing oral NSAIDs for low back pain, think about appropriate clinical 
assessment, ongoing monitoring of risk factors, and the use of gastroprotective 
treatment.
•  Prescribe oral NSAIDs for low back pain at the lowest effective dose for the shortest 
possible period of time.
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Guideline recommendations and best available evidence regarding paracetamol
An overview of guideline recommendations related to paracetamol (acetaminophen) 
for NSLBP is presented in Table 3. Four out of eight included guidelines recommend 
paracetamol for acute LBP (Australia, Canada, Denmark and The Netherlands). In 
both the Australian and Danish guideline, this recommendation is accompanied by a 
statement that paracetamol has no short-term effect. The Belgian, German, British and 
American guidelines recommend against the use of paracetamol in acute LBP. Only the 
Canadian and German guidelines specifically mentioned chronic LBP; in the former, the 
use of paracetamol is recommended in chronic LBP while the latter advises against using 
this pharmacological treatment for patients with either acute or chronic LBP.
The 2016 Cochrane review concluded that there is no significant difference between 
paracetamol and placebo for pain, quality of life, function, impression of recovery, sleep 
table 2: Guideline recommendations concerning NSAIDs for non-specific low back pain (continued)
Guideline Recommendations
US (2017) •  We recommend that the choice between NSAIDs and SMRs be individualized on 
the basis of patient preferences and likely individual medication risk profile.
•  Clinicians should therefore assess renovascular and gastrointestinal risk factors 
before prescribing NSAIDs and recommend the lowest effective doses for the 
shortest periods necessary.
•  Although they are associated with lower risk for adverse effects than nonselective 
NSAIDs, COX-2–selective NSAIDs were not assessed for improvement in pain or 
function.
•  Pharmacologic therapy should be considered for patients with chronic low back 
pain who do not improve with nonpharmacologic interventions. Nonsteroidal 
anti-inflammatory drugs had a small to moderate effect on pain (moderate-quality 
evidence) and no to small effect on function (low-quality evidence) and should be 
the first option considered.
•  Moderate-quality evidence showed no difference in pain improvement when 
different NSAIDs were compared with one another.
Best available 
evidence
Main findings
Non-steroidal 
anti-inflammatory 
drugs for spinal 
pain: a systematic 
review and meta-
analysis. (2017)
•  NSAIDs reduced pain and disability, but provided clinically unimportant effects over 
placebo.
•  Six participants (95% CI 4 to 10) needed to be treated with NSAIDs, rather than 
placebo, for one additional participant to achieve clinically important pain 
reduction.
•  When looking at different types of spinal pain, outcomes or time points, in only 
3 of the 14 analyses were the pooled treatment effects marginally above our 
threshold for clinical importance.
•  NSAIDs increased the risk of gastrointestinal reactions by 2.5 times (95% CI 1.2 to 
5.2), although the median duration of included trials was 7 days.
CI: confidence interval; COX-2: Cyclo-oxygenase 2; LBP: low back pain; NSAID: non-steroidal anti-inflam-
matory drug; PPI: proton pump inhibitor; UK: United Kingdom; US; United States of America.
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table 3: Guideline recommendations concerning paracetamol for non-specific low back pain
Guideline Recommendations
Australia (2016) •  Regular paracetamol is recommended for acute LBP. However, both clinician 
and patients should be mindful that a recent trial demonstrated it was no 
more effective than a placebo plus ‘best evidence education’.
•  If during the course of treatment, patients find that paracetamol is not 
helping, then cessation and review for additional analgesia, such as non-
steroidal anti-inflammatory drugs (NSAIDs), is suggested.
Belgium (2017) •  Do not routinely offer paracetamol (as single medication) for managing low 
back pain with or without radicular pain.
Canada (2017) •  Acute low back pain: Prescribe medication, if necessary, for pain relief 
preferably to be taken at regular intervals. First choice acetaminophen; 
second choice NSAIDs.
•  Chronic low back pain: Recommend acetaminophen and NSAIDs.
Denmark (2018) •  Do only offer patients with recent onset LBP paracetamol in addition to usual 
care after careful consideration, as the evidence points towards no short-term 
effect.
Germany (2017) •  In the light of new evidence, paracetamol ( = acetaminophen) should no 
longer be used. In comparison to placebo, the use of this drug did not lead to 
any improvement in pain or functional ability in patients with either acute or 
chronic non-specific low back pain.
The Netherlands (2017) •  Paracetamol may be prescribed regularly or as-needed; there is no difference 
in effectiveness.
•  NSAIDs are not expected to be more effective than paracetamol for low back 
pain.
UK (2017) •  Do not offer paracetamol alone for managing low back pain.
US (2017) •  The updated evidence showed that acetaminophen was not effective at 
improving pain outcomes versus placebo. […] we recommend against these 
drugs for treatment of acute low back pain.
Best available evidence Main findings
Paracetamol for low 
back pain (Cochrane 
review, 2016)
•  For acute LBP, there is high-quality evidence for no difference between 
paracetamol (4 g per day) and placebo at 1 week (immediate term), 2 weeks, 
4 weeks, and 12 weeks (short term) for the primary outcomes.
•  There is high-quality evidence that paracetamol has no effect on quality of 
life, function, global impression of recovery, and sleep quality for all included 
time periods.
•  There were also no significant differences between paracetamol and placebo 
for adverse events, patient adherence, or use of rescue medication.
•  For chronic LBP, there is very low-quality evidence (based on a trial that has 
been retracted) for no effect of paracetamol (1 g single intravenous dose) on 
immediate pain reduction.
•  Finally, no trials were identified evaluating patients with subacute LBP.
LBP: low back pain; g: grams; NSAID: non-steroidal anti-inflammatory drug; UK: United Kingdom; US; 
United States of America.
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quality, AEs, patient adherence and rescue medication in patients with acute LBP (26). 
There is low quality evidence for no effect of paracetamol in chronic LBP (26).
Paracetamol is generally perceived as safe, but this perception may be misguided (43, 
44). Although severe AEs of paracetamol are relatively rare, paracetamol remains the 
leading cause of acute liver failure worldwide and overdosing may lead to severe liver 
damage and even death (37, 45). Apart from hepatotoxicity, a review of observational 
studies suggests that paracetamol may be associated with an increased risk of cardiovas-
cular, gastrointestinal and renal AEs (respective risk ratios 1.19 – 1.68, 1.11 – 1.49 and 
1.40 – 2.19) (44).
Guideline recommendations and best available evidence regarding 
antidepressants
An overview of guideline recommendations related to antidepressants for NSLBP is 
presented in Table 4. The American, British and Dutch guidelines recommend against 
prescribing antidepressants for LBP. It is stated in the Canadian guideline that insufficient 
evidence exists to recommend antidepressants or for acute LBP. For those with chronic 
LBP with or without leg pain, this guideline suggests TCA’s may have a small to moderate 
effect on pain. The guideline from Belgium advises against prescribing antidepressants 
to patients with acute LBP and against prescribing selective serotonin reuptake inhibitors 
(SSRIs) for those with chronic LBP, but keeps the prescription of tricyclic antidepressants 
(TCAs) or selective serotonin and noradrenalin reuptake inhibitors (SNRIs) for patients 
with chronic LBP open for consideration. The Danish and German guidelines make no 
recommendations for or against prescribing antidepressants in LBP; the Australian guide-
line only makes recommendations about antidepressants for those with neuropathic 
pain; for this reason, these recommendations were not included in this review.
The recent systematic review on pharmacologic therapies for low back pain was con-
sidered to be the best available evidence for the prescription of antidepressants for LBP 
in primary care (30). The effects of antidepressants were not evaluated in patients with 
acute LBP (30). For antidepressants in chronic LBP, no difference in the effect on pain was 
found between TCAs and SSRIs and placebo (30); antidepressants were not associated 
with reduced depression or improved function in patients with chronic LBP (30). Small 
but significant effects were found for duloxetine, an SNRI (30).
The AEs of antidepressants have been summarized in a recent review and meta-anal-
ysis (46). This study found that dry mouth, dizziness, nausea, headache and constipation 
were most often reported by patients; the overall risk ratios for AEs ranged from 1.06 for 
milacipran to 3.78 for fluoxetine (46).
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table 4: Guideline recommendations concerning antidepressants for non-specific low back pain
Guideline Recommendations
Australia (2016) -
Belgium (2017) •  Do not offer selective serotonin reuptake inhibitors (SSRI) for 
managing low back pain with or without radicular pain.
•  Do not routinely offer tricyclic antidepressants or non-
selective serotonin–norepinephrine reuptake inhibitors 
(SNRI) for managing low back pain with or without radicular 
pain. This recommendation is applicable only for chronic 
pain; the use of antidepressants is not recommended in 
acute pain.
Canada (2017) •  Acute low back pain: There is insufficient evidence to 
recommend for or against analgesic antidepressants such as 
amitriptyline, other tricyclic antidepressants, or serotonin-
norepinephrine reuptake inhibitors (SNRIs) for acute low 
back pain with or without leg dominant pain.
•  Chronic low back pain: Tricyclic antidepressants amitriptyline 
and nortriptyline may have a small to moderate effect for 
chronic low back pain with or without leg dominant pain at 
much lower doses than might be used for depression.
Denmark (2018) -
Germany (2017) -
The Netherlands (2017) •  The use of neuropathic pain medication, such as anti-
depressants and anti-convulsants, is not recommended for 
the reduction of pain.
UK (2017) •  Do not offer selective serotonin reuptake inhibitors, 
serotonin–norepinephrine reuptake inhibitors or tricyclic 
antidepressants for managing low back pain.
US (2017) •  Moderate-quality evidence showed that TCAs did not 
effectively improve pain or function (low-quality evidence) 
in patients with chronic low back pain, which is contrary to 
the 2007 guideline. In addition, moderatequality evidence 
showed that SSRIs did not improve pain.
Best available evidence Main findings
Antidepressants: Systemic 
Pharmacologic Therapies for Low 
Back Pain: A Systematic Review for an 
American College of Physicians Clinical 
Practice Guideline (2017)
•  No trial evaluated antidepressants or antiseizure 
medications for acute low back pain.
•  For chronic low back pain, no significant difference was 
found in pain between tricyclic antidepressants or selective 
serotonin reuptake inhibitors and placebo.
•  Antidepressants were not associated with reduced 
depression or improved function.
•  Small but significant effects were found for the serotonin 
norepinephrine reuptake inhibitor (SNRI) duloxetine when 
compared to placebo.
SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; UK: 
United Kingdom; US; United States of America.
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Guideline recommendations and best available evidence regarding 
anticonvulsants
An overview of guideline recommendations related to anticonvulsants for NSLBP is 
presented in Table 5. The Belgian, British and Dutch guidelines recommend against using 
anticonvulsants. It is stated in the Canadian guideline that insufficient evidence exists to 
recommend anticonvulsants for acute LBP; no recommendation is made in this guideline 
about the prescription of anticonvulsants in chronic LBP. The Danish and German guide-
lines make no recommendations for or against prescribing anticonvulsants in
LBP. The guideline from the US does not make a clear recommendation on the use of 
anticonvulsants either; however, it is mentioned elsewhere in the guideline document 
that insufficient evidence exists to make a recommendation about using anticonvulsants 
in LBP. The Australian guideline only makes recommendations about anticonvulsants for 
those with neuropathic pain; for this reason, these recommendations were not included 
in this review.
A systematic review of the commonly used anticonvulsants gabapentin and pregabalin 
concluded that the existing evidence for the efficacy of these drugs for chronic LBP is 
limited, while they are associated with substantial risk of AEs as well as high costs (31). 
table 5: Guideline recommendations concerning anticonvulsants for non-specific low back pain
Guideline Recommendations
Australia (2016) -
Belgium (2017) •  Do not offer anticonvulsants for managing low back pain with 
or without radicular pain in absence of a neuropathic pain 
component.
Canada (2017) •  Acute low back pain: There is insufficient evidence to 
recommend for or against anticonvulsants (gabapentin, 
topiramate) for acute low back pain with or without leg 
dominant pain.
Denmark (2018) -
Germany (2017) -
The Netherlands (2017) •  The use of neuropathic pain medication, such as anti-
depressants and anti-convulsants, is not recommended for 
the reduction of pain.
UK (2017) •  Do not offer anticonvulsants for managing low back pain.
US (2017) -
Best available evidence Main findings
Anticonvulsants: Benefits and safety 
of gabapentinoids in chronic low back 
pain: A systematic review and meta-
analysis of randomized controlled trials 
(2017)
•  Existing evidence on the use of gabapentinoids in CLBP is 
limited and demonstrates significant risk of adverse effects 
without any demonstrated benefit.
•  Given the lack of efficacy, risks, and costs associated, the use 
of gabapentinoids for CLBP merits caution.
CLBP: chronic low back pain; UK: United Kingdom; US; United States of America.
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When compared with placebo, patients using gabapentin were more likely to report diz-
ziness (risk ratio 1.99), fatigue (risk ratio 1.85), difficulties with mentation (risk ratio 3.34) 
and visual disturbances (risk ratio 5.72) (37, 47).
Guideline recommendations and best available evidence regarding muscle 
relaxants
An overview of guideline recommendations related to muscle relaxants for NSLBP is 
presented in Table 6. There are significant variations between guidelines in their recom-
mendations on the prescription of muscle relaxants for LBP. The guidelines from Belgium 
and The Netherlands recommend against prescribing muscle relaxants in LBP. The Cana-
dian guideline only recommends the prescription of muscle relaxants to patients with 
acute LBP in which pain reduction could not be achieved with paracetamol or NSAIDs. 
For chronic LBP, the guideline from Canada states that skeletal muscle relaxants (SMRs) 
may be appropriate for symptomatic relief in selected patients.
Meanwhile, the American guideline recommends SMRs as one of its first choice anal-
gesics, together with NSAIDs; the document states that the choice between NSAIDs and 
SMRs should be made based on patient preferences and risk profiles. This guideline does 
warn clinicians for the AEs associated with SMRs.
The Australian, British, Danish and German guidelines make no recommendations for 
or against prescribing benzodiazepines or SMRs in LBP. However, the British guideline 
does recommend more research should be done to assess the effectiveness of benzo-
diazepines, as current evidence in the field of muscle relaxants is either insufficient to 
make a recommendation or concerns medications that are not licensed for use in the UK 
(SMRs such as cyclobenzaprine and carisoprodol).
A 2017 systematic review and meta-analysis was used as best available evidence for 
the efficacy of muscle relaxants; drug groups considered are both benzodiazepines and 
SMRs (32). This review provides evidence for a clinically significant short-term effect of 
SMRs on pain relief in acute LBP (21.3 points difference on a 100-point pain scale (95% CI 
13.5-29.0 points))(32). For chronic LBP, the efficacy of muscle relaxants remains unknown 
(32). No evidence exists for the efficacy of benzodiazepines in LBP (32).
Common AEs of muscle relaxants include headache, nausea and dizziness (32, 37); 
the AE rate for muscle relaxants was found to be similar to that of placebo (14.1% versus 
16.0%) (32). Benzodiazepines are known to carry a substantial risk of misuse (3% of us-
ers) or drug dependence (2% of users) (48).
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table 6: Guideline recommendations concerning muscle relaxants for non-specific low back pain
Guideline Recommendations
Australia (2016) -
Belgium (2017) •  Do not offer skeletal muscle relaxants for managing low back pain 
with or without radicular pain.
Canada (2017) •  Acute low back pain: Only consider adding a short course 
of muscle relaxant (benzodiazepines, cyclobenzaprine, 
or antispasticity drugs) on its own, or added to NSAIDs, if 
acetaminophen or NSAIDs have failed to reduce pain.
•  Chronic low back pain: Muscle relaxants (e.g., cyclobenzaprine) 
may be appropriate in selected patients for symptomatic relief of 
pain and muscle spasm.
Denmark (2018) -
Germany (2017) -
The Netherlands (2017) •  Benzodiazepines are not recommended. A positive effect of 
muscle relaxation on pain or function has not been demonstrated. 
Meanwhile, these medicaments do have side-effects and a risk of 
dependence exists.
UK (2017) -
US (2017) •  We recommend that the choice between NSAIDs and SMRs 
be individualized on the basis of patient preferences and likely 
individual medication risk profile.
•  Skeletal muscle relaxants are associated with central nervous 
system adverse effects, especially sedation.
Best available evidence Main findings
Efficacy and tolerability of muscle 
relaxants for low back pain: 
Systematic Review and meta-
analysis (2017)
•  A total of five trials (496 participants) provide high quality evidence 
that muscle relaxants provide clinically significant pain relief in the 
short term for acute LBP; MD -21.3, [-29.0, -13.5]. There was no 
information on long-term outcomes.
•  The median adverse event rate in clinical trials for muscle 
relaxants was similar to placebo 14.1% IQR (7.0–28.7%) and 16.0% 
(4.1–31.2%); p = 0.5, respectively.
•  There is no evidence for the efficacy of benzodiazepines in LBP.
•  For people with acute LBP, muscle relaxants provide clinically 
significant short-term pain relief.
•  For chronic LBP, the efficacy of muscle relaxants is largely 
unknown. There was no eligible RCT evidence to support the 
efficacy of benzodiazepines in LBP. Prolonged use of these 
medicines in LBP cannot be guided by trial evidence.
IQR: interquartile range; LBP: low back pain; MD: mean difference; NSAID: non-steroidal anti-inflam-
matory drug; RCT: randomized controlled trial; SMR: skeletal muscle relaxant; UK: United Kingdom; US; 
United States of America.
39
Guideline recommendations for pharmacotherapy
2
concLuSion
Eight national clinical practice guidelines for the management of LBP have been updated 
in the last three years. This review aimed to compare the recommendations for pharma-
cological treatment of NSLBP in primary care of these guidelines with the best available 
evidence regarding treatment efficacy; these recommendations may not apply to pa-
tients for whom a specific cause for LBP has been identified. The findings from systematic 
reviews that were considered to be best available evidence are echoed in most of the 
included clinical practice guidelines. Differences exist between guidelines in terms of the 
first-line analgesic in acute LBP. Although best available evidence suggests paracetamol 
is ineffective in acute LBP, four out of eight guidelines still recommend prescribing 
paracetamol for this condition. However, two of these guidelines immediately state that 
no short-term effect of this medication is to be expected. In the other four guidelines, 
NSAIDs have become the first choice analgesics in LBP; in the American guideline, clini-
cians are encouraged to choose between NSAIDs and SMRs based on preferences and 
risk profile of the patient.
When compared to the previous generation of clinical practice guidelines, where pre-
scription of time-contingent paracetamol or NSAIDs was considered the norm(13), this 
generation is universally moving away from recommending pharmacotherapy, presenting 
the prescription of analgesics as an option that may be considered if this is required by 
the patient. The guidelines from Denmark and the US seem to be the most progressive in 
this respect, actively discouraging the pharmacological treatment of NSLBP and recom-
mend non-pharmacological options instead.
As has been recently demonstrated in Australian data, opioids are now the most pre-
scribed analgesics for LBP in primary care. All guidelines consider opioids as a last resort 
option in case all other pharmacological options have failed, but opinions differ concern-
ing reassessment intervals and treatment duration in general. Only limited evidence ex-
ists for the efficacy of antidepressants and anticonvulsants in chronic LBP; best available 
evidence does suggest a small but significant effect of duloxetine (an SNRI) for chronic 
LBP. Regarding recommendations about muscle relaxants, the field is most divided: four 
guidelines don’t make any recommendations for or against muscle relaxants, while two 
countries advise against the prescription of this medication, one guideline only recom-
mends muscle relaxants to selected patients and, as mentioned above, the last guideline 
(from the US) considers SMRs as one of the analgesics of first choice.
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eXPert oPinion
In general, most clinical practice guideline recommendations match review findings. 
However, pharmacological treatments such as paracetamol and anticonvulsants which 
have not been shown to be effective in RCTs are still recommended in a number of 
guidelines. Furthermore, pharmacological treatments for which efficacy has been dem-
onstrated, such as NSAIDs and opioids, only have small to moderate effects at best at the 
immediate term and short term. Meanwhile, all pharmacological treatments discussed 
in this article are associated with risks of AEs. This means careful consideration is prudent 
before recommending the use of any analgesic to patients with NSLBP; this notion has 
been incorporated in some form or another in all clinical practice guidelines, but could 
be presented more prominently in some.
Based on the available evidence, NSAIDs and SMRs may be the best possible drug 
choices in case pharmacotherapy is deemed absolutely necessary for the management 
of NSLBP. However, in Australia and several European countries, SMRs have not been 
registered due to risk of abuse or addiction, automatically making NSAIDs the analgesics 
of first choice. The only guideline discussing NSAIDs and SMRs as equal options is the 
American guideline; this document however does not provide clear patient characteris-
tics on which a choice between these pharmacological treatments can be based; instead, 
it recommends individualizing this choice “on the basis of patient preferences and […] 
individual medication risk profile”. This feels like a step away from the ‘one size fits all’ 
approach of RCTs and corresponding meta-analyses and towards the unpredictability of 
clinical practice, although there currently is insufficient information available to deter-
mine what medication to prescribe to individual patients in order to maximize treatment 
effect. Guiding clinicians in personalized medical decisions is a challenge for researchers, 
and this task is complicated by the fact that NSLBP is a heterogeneous disorder and most 
RCTs are insufficiently powered to identify subgroups or individuals using typical subgroup 
analyses (49-51); furthermore, it is often unclear whether observed improvements in 
LBP symptoms of individual patients are attributable to medication effects or explained 
by other phenomena such as natural recovery. Alternative statistical approaches such as 
individual participant data meta-analysis (IPDMA) may be helpful in creating personalized 
medicine strategies (50); research protocols have been published for IPDMA of exercise 
therapy and spinal manipulative therapy for chronic LBP (52, 53). So far, no protocols for 
IPDMA of pharmacological treatments in LBP have been published.
According to the best available evidence, paracetamol has no effect on the outcomes 
of LBP when compared to placebo. However, one should realize that this evidence is 
mainly based on a single, though large RCT; quality of evidence regarding the efficacy 
of paracetamol in LBP is therefore considered to be low in some guidelines (16, 22). 
Therefore, it is important to replicate the aforementioned efficacy trial, comparing 
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paracetamol not only to placebo, but also to other available (non-)pharmacological treat-
ment alternatives in order to strengthen recommendations in future guidelines.
The prescription of anticonvulsants and antidepressants for NSLBP should be recom-
mended against in future primary care clinical practice guidelines, as these pharmacologi-
cal treatments should be reserved for patients with neuropathic pain, which is unlikely 
to be non-specific. As already stated in the current American guideline, opioids should 
only be prescribed as a last resort; we suggest new guidelines provide clinicians with 
clear instructions for duration of treatment and regular reassessment of patients taking 
opioids, similar to the current recommendations in the Dutch guidelines.
Although most of the guidelines discussed in this article already are hesitant in their 
recommendations to prescribe analgesics as stated above, none of the publications is 
as strict as the American guideline, which specifically states that non-pharmacological 
treatments should be first selected for the treatment of acute NSLBP, as most patients will 
improve regardless of treatment. The German guideline echoes this recommendation, 
stating that the treatment of LBP with drugs is purely symptomatic and should only be 
prescribed in support of non-pharmacological measures. In spite of these recommenda-
tions, pharmacotherapy for NSLBP is still ubiquitous in clinical practice and both patients 
and clinicians often do not consider analgesics to be merely optional. Most alarmingly, 
there has been a marked increase in the prescription of opioids for non-cancer pain in 
recent years. This trend was initially seen in the US and Canada (38), but the number 
of opioid prescriptions has increased in other parts of the world as well (54, 55). This 
development may reflect a continuing focus on pain rather than function in the field of 
NSLBP.
We consider the fact that many NSLBP patients still routinely receive analgesic prescrip-
tions as a major challenge for the future, especially in the case of opioids. The authors 
believe that upcoming guideline updates should therefore follow the American example 
and explicitly shift their focus from pain to function and from pharmacotherapy to 
non-pharmacological treatment options (8). Of course this means non-pharmacological 
treatment options should be credible and feasible; this is where a challenge lies for 
researchers in the field of NSLBP, as evidence is limited for comparative effectiveness be-
tween pharmacological and non-pharmacological treatment options as well as between 
different non-pharmacological treatment options.
Apart from the recommendations made by guidelines, special attention should be 
given to the translation of these recommendations to clinical practice. It has been shown 
that there still are evidence-practice gaps in the management of LBP (56-58). Miscon-
ceptions about back pain and focus on a pathophysiological model of care have been 
identified as barriers to successful implementation of LBP guidelines (59) and excellent 
initiatives for improving the implementation of guideline recommendations have already 
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been developed (8); using these strategies on a larger scale may lead to an increased 
uptake of guidelines and consequently to an improvement in quality of LBP care.
Changing treatment routines from pharmacotherapy to non-pharmacological treat-
ment is not only a challenge for clinicians, but also for NSLBP patients, who will need to 
understand and accept these changes. Public health interventions such as mass media 
campaigns to educate patients about the limited benefits and side effects of medication 
could be a first step in order to achieve this (60); media campaigns have been proven to 
be successful in changing patients beliefs and behaviors in the past (8). Another possible 
approach to changing NSLBP patients’ beliefs and behaviors may be through patient 
information websites (61) or using consumer versions of guidelines (62, 63). If both clini-
cians and patients see the benefits of avoiding analgesics, the rise in prescriptions to 
NSLBP patients could be halted and maybe even reversed.
As most LBP guidelines are updated approximately every ten years, we don’t expect 
any major changes in policy or clinical practice in the upcoming years. However, we hope 
new evidence for non-pharmacological treatment options, increased focus on guideline 
implementation and patient education through mass media campaigns, patient informa-
tion websites and consumer versions of guidelines can help to slowly steer physicians and 
patients towards non-pharmacological treatments as the interventions of first choice for 
NSLBP, with improved quality of care as a result.
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ABStrAct
Introduction
Low back pain is common and associated with a considerable burden to patients and 
society. There is uncertainty regarding the relative benefit of paracetamol and diclofenac 
and regarding the additional effect of pain medication compared with advice only in 
patients with acute low back pain. This trial will assess the effectiveness of paracetamol, 
diclofenac and placebo for acute low back pain over a period of 4 weeks. Furthermore, 
this trial will assess the additional effectiveness of paracetamol, diclofenac and placebo 
compared with advice only for acute low back pain over a period of 4 weeks.
Methods
The PACE Plus trial is a multi-center, placebo-blinded, superiority randomized controlled 
trial in primary care, with a follow-up of 12 weeks. Patients with acute low back pain aged 
18-60 years presenting in general practice will be included.
Patients are randomized into four groups: 1) Advice only (usual care conforming 
with the clinical guideline of the Dutch College of General Practitioners); 2) Advice and 
paracetamol; 3) Advice and diclofenac; 4) Advice and placebo. The primary outcome 
is low back pain intensity measured with a numerical rating scale (0-10). Secondary 
outcomes include compliance to treatment, disability, perceived recovery, costs, adverse 
reactions, satisfaction, sleep quality, co-interventions and adequacy of blinding.
Between group differences for low back pain intensity will be evaluated using a re-
peated measurements analysis with linear effects models. An economic evaluation will 
be performed using a cost-effectiveness analysis with low back pain intensity and a cost-
utility analysis with quality of life. Explorative analyses will be performed to assess effect 
modification by predefined variables.
Ethical approval has been granted. Trial results will be released to an appropriate peer-
viewed journal.
discussion
This paper presents the design of the PACE Plus trial: a multi-center, placebo-blinded, 
superiority randomized controlled trial in primary care that will assess the effectiveness 
of advice only, paracetamol, diclofenac and placebo for acute low back pain.
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introduction
Low back pain is one of the most common diseases of the musculoskeletal system. It is 
associated with a considerable burden to patients and society. According to the global 
burden of disease study, low back pain is the number one disorder responsible for dis-
ability in the population (as calculated by the years lived with disability (YLD)) (1). The 
point prevalence is reported to be as high as 33%. The total costs associated with back 
pain in The Netherlands are estimated at 3,5 billion euro in 2007 (2). In the United States, 
the figure is over US$50 billion (3).
Clinical guidelines for the management of low back pain have been issued in many 
countries around the world in order to promote rational care (4). These guidelines 
provide clear agreement on the recommendations for first line care of acute low back 
pain (4). According to most guidelines, first line care should consist of reassurance on 
the favorable prognosis of non-specific low back pain, advice to stay active and avoid 
bed rest, and prescription of a simple analgesic medicine using a time-contingent dose 
regimen, e.g. 1 g paracetamol administered 4 times per day. The clinical guideline for the 
management of low back pain of the Dutch College of General Practitioners (NHG) also 
recommends paracetamol as first choice followed by nonsteroidal anti-inflammatory 
drugs (NSAIDs) as a second option for the prescription of analgesics for patients with 
acute low back pain (5). The current guideline preference for paracetamol as the first 
choice analgesic was not based on evidence on its efficacy in patients with back pain, but 
on its better safety-profile as compared to NSAIDs and other analgesics. Until recently 
there was no placebo-controlled trial available evaluating the effect of paracetamol for 
patients with low back pain.
In July 2014, the first placebo controlled trial of paracetamol for acute low back pain 
(PACE trial) was published (6). Australian researchers showed no difference in clinical 
outcomes between paracetamol and placebo in patients with acute low back pain. In 
this large clinical trial, 1652 patients with acute low back pain were randomized to 1) 
paracetamol on regular doses 2) paracetamol as needed or 3) placebo. Neither on the 
primary outcome (time to recovery) nor on any secondary outcome such as back pain 
intensity, disability, symptom change were differences in outcome between the three 
study groups found (6).
Considering the findings in this Randomized-Controlled Trial (RCT), one relevant ques-
tion is if the current clinical guideline recommendations should be changed regarding 
the use of paracetamol. The Australian research team stated that replication of their 
study findings should take place before dismissing paracetamol as a treatment option for 
low back pain. Changing the content of guidelines based on the findings of a single trial 
without verification of the results in other similar populations would seem premature 
(7). Besides replication of the paracetamol versus placebo contrast of the PACE trial 
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two other topics are also of importance: firstly, there is ample evidence that the clinical 
course of many patients with acute low back pain is rather favorable. In the PACE trial the 
median recovery was 16-17 days in all participating patients, including those receiving 
placebo, and by 12 weeks about 85% of patients was recovered. All patients in the trial 
received advice and reassurance of a favorable prognosis in addition to the study medi-
cations and apparently did rather well regarding the authors. This raises the question of 
whether patients with acute low back pain need paracetamol (or other analgesic) at all. 
What would be the outcome if patients receive advice and reassurance only?
Secondly, the awareness of the limited clinical effect of paracetamol could easily 
influence the decision to step up more quickly to using NSAIDs which are the next rec-
ommended type of pain medication in the clinical guidelines. Should NSAIDs even be 
recommended as first analgesic treatment option instead of paracetamol for patients 
with acute low back pain? NSAIDs have been compared with placebo in patients with 
low back pain and have shown significantly better results for pain reduction (8). However, 
the magnitudes of the effects are rather small. The between-group differences were less 
than 10 points on a 0-100 pain scale. In addition, in direct comparisons NSAIDs have not 
shown consistent superiority above paracetamol in patients with acute low back pain. 
The Cochrane review only lists 5 RCTs comparing NSAIDS versus paracetamol and all were 
at risk for high risk of bias (8). The Cochrane review concluded ‘whether NSAIDs are more 
effective than other drugs or non-drug therapies for acute low-back pain still remains 
unclear’. In the Netherlands, diclofenac has been the most commonly prescribed NSAID 
over the past decade (9).
objective
The primary objective of the PACE Plus trial is to compare the clinical effectiveness of 
paracetamol, diclofenac and placebo for acute low back pain in primary care over 4 weeks 
of follow-up. Furthermore, this trial aims to determine the added clinical effectiveness of 
medication and advice (paracetamol, NSAID or placebo) versus advice only for acute low 
back pain in primary care over 4 weeks of follow-up. Secondary objectives of the PACE 
Plus trial are to compare disability, patients’ perceived recovery, quality of life, costs, time 
to recovery, compliance to treatment, adverse reactions, patients’ satisfaction, sleep 
quality and co-interventions between advice plus paracetamol, advice plus diclofenac, 
advice plus placebo and advice only groups.
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MethodS
Trial design and setti  ng
The trial will be a four arm, multi center, placebo-blinded, superiority randomized con-
trolled trial using double dummy technique in general practi ce with a follow-up period 
of 12 weeks. The study design and fl ow of pati ents in the PACE Plus trial are shown in 
Figure 1.
 
Assessment for eligibility
Exclusion
   Did not meet inclusion criteria
   Declined to participate
   Other reasons
 Follow-up complete
 Lost to follow-up
 Discontinued 
intervention
Allocated to advice 
only
 Received allocated 
intervention  
 Did not receive 
allocated intervention  
Randomization
1.1 Enrollment 
Allocated to advice + 
paracetamol
 Received allocated 
intervention  
 Did not receive 
allocated intervention  
Allocated to advice + 
diclofenac
 Received allocated 
intervention  
 Did not receive 
allocated intervention 
1.2 Allocation 
Allocated to advice +
placebo
 Received allocated 
intervention  
 Did not receive 
allocated intervention  
Analysis
 
 Follow-up complete
 Lost to follow-up
 Discontinued 
intervention
 Follow-up complete
 Lost to follow-up
 Discontinued 
intervention
 Follow-up complete
 Lost to follow-up
 Discontinued 
intervention
1.3 Follow-Up 
Analysis
 
Analysis
 
Analysis
 
1.4 Analysis 
Diagnosis Non-specific Low Back Pain
Advice (usual care conforming with 
Dutch clinical guidelines for GPs
figure 1: Flow-chart of the PACE Plus trial.
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The patient eligibility criteria of the PACE trial are similar to the in- and exclusion criteria 
that will be used in the PACE Plus trial. Based on the figures in the PACE trial, we will need 
to assess at least 2231 patients to end up with 800 patients that fulfill eligibility criteria 
and are willing to participate in the trial. In the PACE trial, 4606 patients were screened 
by 235 primary care providers during a recruitment period of 3.5 years. This comes down 
to an average of 5.6 patients per primary care provider per year. The PACE Plus trial has a 
planned recruitment period of 2 years. We thus need cooperation of at least 200 General 
Practitioners (GPs) for the referral of patients with acute low back pain for screening. 
Based on the Dutch National Assessment of Diseases in Primary Care (10), in the aver-
age Dutch general practice, the incidence of low back pain is 27 per 1000 patients per 
year; we therefore assume the proposed referral rate is feasible. Recruitment rate will be 
monitored closely during the trial recruitment period and if necessary, more GPs will be 
contacted for participation.
Participants and eligibility criteria
Patients will be recruited in Dutch general practices and referred to the PACE Plus re-
search team. Before enrolment in the trial, all potential patients will be assessed for 
eligibility and informed consent.
inclusion criteria
In order to be eligible to participate in this study, a patient must meet all of the following 
criteria: 1) Aged between 18 and 60 years; 2) Low back pain of less than 6 weeks duration; 
3) Primary complaint of pain in the area between the 12th rib and buttock crease, with or 
without radiating leg pain; 4) Experiencing a new episode of low back pain, preceded by 
a period of at least one month without low back pain; 5) Low back pain severe enough to 
cause at least moderate pain (≥ 4 on 0-10 numerical rating scale (NRS)).
exclusion criteria
A potential patient who meets any of the following criteria will be excluded from par-
ticipation in this study: 1) known or suspected serious spinal pathology (e.g. metastatic, 
inflammatory or infective diseases of the spine, cauda equina syndrome, spinal fracture); 
2) Currently taking recommended regular doses of analgesics, including paracetamol or 
diclofenac; 3) Spinal surgery within the preceding 6 months; 4) Serious co-morbidities 
like severe rheumatoid arthritis, cardiac failure, diabetes preventing prescription of 
paracetamol (e.g.: liver or renal failure) or diclofenac (e.g. gastric ulcers or other gastro-
intestinal problems); use of proton pump inhibitors before inclusion is not an exclusion 
criterium, as the patient is considered to be protected (patient will have to continue 
using this medication during use of study medication); 5) Use of coumarine derivatives, 
clopidogrel, prasugrel, ticagrelor, acetylsalicylacid derivatives, systemic glucocorticoid, 
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selective serotonin reuptake inhibitors (SSRIs), venlafaxine, duloxetine, trazodone, spi-
ronolactone or other medications that may interact with paracetamol and/or diclofenac; 
6) Known intolerance for paracetamol and/or diclofenac; 7) Pregnant or planning to 
become pregnant during the treatment period.
recruitment
Patients consulting their GP or doctor’s assistant for low back pain and fulfilling simple 
referral criteria (ages 18 to 60 years, new episode of low back pain (6 weeks maximum 
duration) and no contraindications for diclofenac) can be referred to the PACE Plus re-
search team. Potential participants will be contacted within 24 hours by a researcher for 
further information about the trial, assessment of the eligibility criteria and collection of 
informed consent.
randomization and blinding
After collection of informed consent, patients will be randomly allocated to one of four 
intervention groups: 1 advice only group and 3 medication groups. Randomization will 
be performed using a two-step process. In the first step, patients will be randomized 
between ‘advice only’ and ‘medication’ using a computer-generated randomization list. 
After the first step of the randomization process, patients and GPs will be informed about 
the outcome of treatment allocation (either that they receive advice only or that they 
receive blinded study medication).
In the advice only group, patients will not get study medication, but receive advice 
and reassurance from their GP or doctor’s assistant only (usual care conforming with the 
clinical guideline of the Dutch College of GPs).
For people who are randomized in the first step to ‘medication’, a trial medication 
prescription will be sent to the Erasmus University Hospital Trial Pharmacy. In the second 
step of randomization, an independent trial pharmacist will use a randomization list with 
random blocks to determine the medication group that patients will be randomized to 
(paracetamol, diclofenac or placebo). Both randomization lists used in this two-step 
process are made by an independent data-manager who is not involved in this trial.
After allocation to 1 of the 3 medication groups, patients will receive a treatment pack 
containing large oblong tablets and small round tablets prepared and numbered by an 
independent trial pharmacist. Treatment packs will be sent by mail to the patient, and 
are expected to arrive the next day. Using the double dummy technique, active medica-
tion differs between groups as follows:
- Paracetamol group: active oblong tablets (active paracetamol) and placebo round 
tablets (placebo diclofenac);
- Diclofenac group: placebo oblong tablets (placebo paracetamol) and active round 
tablets (active diclofenac);
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- Placebo group: placebo oblong tablets (placebo paracetamol) and placebo round 
tablets (placebo diclofenac).
The placebo tablets that will be used in the PACE Plus trial are identical in appearance 
and taste to their active counterparts, but do not contain the active component. All 
medication packaging will be identical between the 3 medication groups, except for a 
unique randomization number for each participant. Every package contains a reply paid 
post envelope, in which unused tablets can be returned for counting after 4 weeks of 
follow-up. The patient, patient’s GP and pharmacist and researchers involved in data col-
lection and analysis will be blind to treatment group allocation. Unblinding is permissible 
in case of a reported suspected unexpected serious adverse reaction (SUSAR).
treatment
All patients in the PACE Plus trial will receive advice and reassurance from either their GP 
or doctor’s assistant before referral (usual care conforming with the clinical guideline of 
the Dutch College of GPs).
Patients in the medication groups will be asked to take 4 daily doses of 2 oblong tablets 
and 2 daily doses of 1 round tablet, until they have experienced two consecutive pain 
free days (NRS 0 or 1 out of 10), or for a maximum of 4 weeks if a pain free interval does 
not occur. This means that treatment groups will receive the following drug dosages:
- Paracetamol group: paracetamol (immediate release) 4 daily doses of 1000 mg, 
placebo diclofenac 2 daily doses.
- Diclofenac group: diclofenac (immediate release) 2 daily doses of 75 mg, placebo 
paracetamol 4 daily doses.
- Placebo group: placebo paracetamol 4 daily doses, placebo diclofenac 2 daily doses.
Allocated treatment as described above may be discontinued by the patient’s own GP 
in case the patient revisits his or her GP because of persisting low back pain; this will be 
recorded during follow-up measurements.
co-interventions
During participation in the PACE Plus trial, patients in the medication groups will be asked 
not to take paracetamol or NSAIDs because this may lead to overdose of these medica-
tions. Participant’s GP and Pharmacist will be informed about the participation of their 
patient in the PACE Plus trial, and for the medication groups, the usage of trial medica-
tion. Additional medication taken by the patient for low back pain will systematically be 
recorded in patients’ questionnaires at all follow-up measurements. Physiotherapy as a 
co-intervention is allowed, but will also be recorded in follow-up measurements.
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outcomes
The primary outcome of the PACE Plus trial is low back pain intensity measured with an 
11-point NRS (score range 0-10; higher score means more pain). Pain intensity will be 
recorded daily over a 4 week follow up period.
Secondary outcome measures that are collected in the PACE Plus trial are:
• compliance to treatment measured daily by asking ‘How many large, oblong tablets 
did you take today?’ and ‘How many small, round tablets did you take today?’ (ques-
tions derived from the Brief Medication Questionnaire (BMQ) (11)).
• disability measured using the Roland Morris Disability Questionnaire (RMDQ; score 
range 0-24; higher score means more disability) (12).
• patients’ perceived recovery measured using a 7-point Likert scale that will be di-
chotomized into recovered (score 1 ‘complete recovery’ and 2 ‘much improved) and 
not-recovered (score 3 ‘improvement’ to score 7 ‘worse than ever’).
• quality of life measured using the EuroQol Group 5 Dimensions, 5 Level Question-
naire (EQ-5D-5L) (13).
• costs; all direct medical and patient costs measured using the iMedical Consump-
tion Questionnaire (iMCQ), and productivity costs measured with iProductivity Cost 
Questionnaire (iPCQ) (14, 15).
• time to recovery assessed using the daily low back pain severity scores. Recovery is 
defined as the first day of 0 or 1 pain intensity, maintained for seven consecutive days.
• adverse reactions systematically recorded in the follow-up questionnaires; all report-
ed adverse events will be followed until they have abated or until a stable situation 
has been reached.
• patients’ satisfaction measured using an 11-point NRS; score range 0-10, higher score 
means more satisfaction.
• sleep quality measured using a 4 point Likert scale derived from the Pittsburgh Sleep 
Quality Index (PSQI) (16). Scores will be dichotomized into good sleep quality (score 1 
‘very good’ and 2 ‘fairly good’) and poor sleep quality (score 3 ‘fairly bad’ and 4 ‘very 
bad’).
• co-interventions systematically recorded in the follow-up questionnaires.
• adequacy of blinding assessed in medication groups by asking patients to which treat-
ment group they believe to be allocated after 12 weeks of follow-up.
Baseline characteristics that will be measured in the PACE Plus trial (including potentially 
relevant prognostic factors) are:
• gender, age, height, weight, education and occupational status.
• duration of complaints, history of back complaints, and comorbidity.
• job satisfaction measured with a 7-point Likert scale (score range from extremely 
unsatisfied to extremely satisfied).
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• neuropathic pain measured with the Pain DETECT questionnaire (score range 0-38; 
higher score means a neuropathic component of back pain is more likely) (17).
• potentially modifiable prognostic indicators measured with the StarT Back Tool (18).
Patient timeline and data collection
Table 1 shows the time schedule of patient enrollment, interventions and assessments 
according to the SPIRIT-statement (19). After collection of informed consent, patients will 
fill out the baseline questionnaire. Subsequently, patients will be randomized into one of 
the four treatment groups. Patients will fill out daily digital questions regarding low back 
pain severity and compliance to treatment during 4 weeks after baseline measurement. 
Questionnaires concerning secondary outcomes will be filled out at 2, 4 and 12 weeks 
of follow-up. All questionnaires used in the PACE Plus trial will be sent to participants 
using e-mail and filled out using secure hyperlinks. If a questionnaire is not filled out 
(completely) by a participant, the research team will send a reminder encouraging the 
participant to complete the questionnaire.
Sample size
For the primary outcome (low back pain intensity (NRS)), between group differences of 
at least 20% are considered clinically relevant; this difference is expressed in the area 
under the longitudinal pain trajectories for the four treatment groups. Because low 
back pain is an episodic condition that is known to fluctuate over time, the correlation 
between repeated measured was assumed moderate (the parameter rho of a first-order 
auto-regressive serial correlation structure was set to 0.7). In the sample size calculation, 
a statistical power of 84% and a random dropout not exceeding 15% were assumed. With 
group sizes of 200 patients, a between group difference in low back pain intensity of at 
least 20% can be detected.
Statistical analysis
The statistical analysis will be performed according to the intention-to treat principle.
Primary Statistical analysis
For clinical effectiveness the between group differences for the primary outcome, low 
back pain-intensity will be evaluated using a repeated measurements analysis with 
linear mixed effects models with adequate specification of the fixed and random effects 
structures to account for possible nonlinear effects. The covariance structure will be 
unstructured, but we will compare Akaikes’ information criterion between the different 
covariance structures and choose the structure with the lowest value.
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Secondary Statistical analysis
A similar approach as described in ‘primary study parameter(s)’ will be used for the 
continuous secondary outcomes (e.g. disability and quality of life) to assess between 
group differences.
A Cox proportional hazards model will be carried out to evaluate the difference in time 
to recovery (recovery is defined as seven consecutive low back pain NRS scores of 0-1) 
between the groups.
The effect modification of the allocated treatment strategy by predefined baseline 
variables (explorative) on low back pain intensity, disability and recovery at 4 and 12 
weeks follow-up will be analysed by Cox proportional hazard analyses and logistic regres-
sion analyses, respectively. Predefined variables are severe low back pain (defined as 
NRS≥7) and severe disability (defined as RMDQ≥16) at baseline.
table 1: Schedule of enrolment, interventions and assessments (SPIRIT)
STUDY PERIOD
Enrolment Allocation Post-allocation (Tweeks) Close-out
TIMEPOINT Tbaseline 0 T2 T4 T12
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS: ●────────────────────●
ASSESSMENTS:
Socio-demographics X
Relevant prognostic factors X
LBP Intensity (NRS 0-10) ●────────────────────● X
Compliance to treatment ●────────────────────●
Disability RMDQ (0-24) X X X X
Patient’s perceived recovery 7-point Likert scale X X X
Quality of life EQ-5D-5L (5-25) X X X
Medical consumption iMCQ X X
Productivity loss iPCQ X X
Adverse reactions X X X
Patient’s satisfaction 11-point NRS scale (0-10) X X X
Sleep quality 4-point Likert scale X X X X
Co-interventions X X X
Adequacy of blinding X
LBP = Low Back Pain; NRS = numerical rating scale score; RDMQ = Roland-Morris Disability Questionnaire; 
EQ-5D-5L = EuroQol Group, 5 dimensions, 5 level questionnaire; iMCQ = institute for Medical Technology 
Assessment (iMTA) Medical Consumption Questionnaire; iPCQ = iMTA Productivity Cost Questionnaire.
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To assess the cost-effectiveness of paracetamol versus diclofenac versus advice only for 
acute low back pain in general practice, a cost-effectiveness analysis will be performed 
using the primary outcome low back pain severity (measured daily). A cost-utility analysis 
will be performed to compare our study with other studies in musculoskeletal disorders 
research in a more general accepted outcome e.g. quality of life (measured in Quality-
Adjusted Life Years (QALYs)). Utility values of the Dutch public for EuroQol health states 
will be applied to calculate QALY’s based on the EQ-5D. Using non parametric bootstrap-
ping (randomly drawing 2500 observations with replacement from the patient sample), 
the degree of uncertainty for costs and health effects and the cost-utility ratio will be 
depicted in a cost-effectiveness plane. In addition, an acceptability curve will be drawn, 
which indicates the probability that the paracetamol or diclofenac versus advice only 
has lower incremental costs per QALY gained than various thresholds for the maximum 
willingness to pay for an extra QALY.
The economic analysis will be based on the societal perspective and on the healthcare 
perspective in which the direct and productivity costs in the groups will be compared. 
The costs per hour of productivity loss will be updated from the Dutch Guideline for eco-
nomic evaluations in health care (20). The friction cost method will be used to calculate 
the productivity costs according to the Dutch guidelines. The costs per unit of medical 
consumption will be estimated, using information from the Dutch Manual for economic 
evaluation of health care on costs per unit of medical services (21).
Trial registration
This study protocol was registered with the Dutch Trial Register on September 14th, 2016 
(NTR6089; Protocol: Version 4, June 2016).
data management and safety
All personal data (e.g. demographics, contact-data, questionnaires, diary) will be stored 
anonymously. The patients’ identity will remain confidential at all times. Each patient will 
be allocated a unique code, which will be used on the Case Report Forms (CRFs). The link 
between the code and the patients’ name will only be assessed by the researchers and 
the data-manager.
Trial conduct and data integrity will be audited once per year by independent auditors.
diScuSSion
This paper presents the design for a randomized, placebo controlled trial that will assess 
the effectiveness of paracetamol, diclofenac and placebo for acute low back pain in pri-
mary care. Furthermore, the trial will assess the additional effectiveness of paracetamol, 
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diclofenac and placebo compared to advice only for acute low back pain in primary care. 
The primary outcome is low back pain intensity measured daily on a numerical rating 
scale over a period of 4 weeks. Secondary outcomes are measured at 1 weeks, 2 weeks, 
4 weeks and 12 weeks of follow-up and include compliance to treatment, disability, 
perceived recovery, costs, adverse reactions, satisfaction, sleep quality, co-interventions 
and adequacy of blinding. Between group differences for the primary outcome will 
be evaluated using a repeated measurements analysis with linear effects models. An 
economic evaluation will be performed using a cost-effectiveness analysis with low back 
pain intensity and a cost-utility analysis with quality of life. Explorative analyses will be 
performed to assess effect modification by predefined variables. The outcomes of this 
trial may impact the clinical guideline recommendations concerning first analgesic treat-
ment options in acute low back pain in general practice.
Recruitment of eligible patients is currently ongoing. Substantial protocol amendments 
will be communicated to participants, cooperating GPs and pharmacists, Medical Re-
search and Ethics Committee (MREC), the Dutch Trial Registry, ZonMw and the journal 
publishing this protocol. Results of this trial will be published in a peer-reviewed journal. 
After publication, participating patients and GPs will be informed about trial results 
(expected in 2020).
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ABStrAct
Introduction
The PACE Plus trial was a multi-center, double-blinded, superiority randomized controlled 
trial (RCT) conducted in patients from Dutch general practice to investigate the efficacy of 
paracetamol and NSAIDs in acute non-specific low back pain (LBP). Because insufficient 
numbers of patients could be recruited (only four out of the required 800 patients could 
be recruited over a period of six months), the trial was prematurely terminated in Febru-
ary 2017, six months after the start of recruitment. This article aims to transparently 
communicate the discontinuation of PACE Plus and to make recommendations for future 
studies.
Methods
General Practitioners (GPs) from 36 participating practices received a one-question 
survey in which they were asked to give the three most important factors that in their 
opinion contributed to failure of patient recruitment.
results
GPs of 33 out of 36 (92%) participating practices sent a response. A total of 81 factors 
were reported. These have been categorized into patient factors (26 out of 81 com-
ments, 32%), GP factors (39 out of 81 comments, 48%) and research factors (16 out of 
81 comments, 20%).
discussion
Patient recruitment in the PACE Plus trial may have failed due to inefficient medication 
distribution, recruitment of incident rather than prevalent cases, a design that was too 
complicated, adequate self-management of LBP, patient expectations different from 
the trial’s scope and lack of time of participating GPs. Substantial differences in design 
may explain why the preceding PACE trial did manage to successfully complete patient 
recruitment.
conclusion
Although the PACE Plus trial was terminated as a result of insufficient patient inclusion, 
the research questions addressed in this trial remain relevant but unanswered. We hope 
that lessons learned from the discontinuation of PACE Plus and corresponding recom-
mendations may be helpful in the design of upcoming research projects in LBP in general 
practice.
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introduction
The PACE Plus trial was conducted in Dutch general practice to investigate the efficacy of 
paracetamol and NSAIDs in acute non-specific low back pain (LBP) (1). The study design 
was a multi-center, placebo-blinded, superiority randomized controlled trial (RCT). The 
two main aims of this RCT were to replicate the comparison between paracetamol and 
placebo as done in the PACE trial (2-4) and to compare the efficacy of paracetamol with 
diclofenac and advice only. The study protocol was published (1) and was prospectively 
registered (Dutch Trial Registration NTR6089, registered September 14th 2016). The Eras-
mus MC Medical Research and Ethics Committee (MREC) has granted approval for the 
PACE Plus trial (NL54941.078.16). In short, our intention was to recruit 800 patients with 
acute LBP from Dutch general practices, who would be randomized across four treat-
ment groups (paracetamol, diclofenac, placebo or advice only) and would be followed for 
12 weeks. Inclusion and exclusion criteria for patient recruitment in the PACE Plus trial 
can be found in Table 1.
From May 2016, General Practitioners (GPs) were recruited for participation in the 
trial. Initially, GPs who had experience with patient recruitment in studies conducted by 
the Erasmus Medical Center (EMC) Department of General Practice were approached for 
participation. As a second step in the recruitment of GPs, local GPs from the provinces of 
Zuid-Holland, Noord-Brabant and Zeeland and GPs who were specializing in musculoskel-
etal disorders at the EMC were approached for participation. Finally, GP residents in their 
last year of training were asked to participate as part of their training program.
Recruitment of eligible patients for the PACE Plus trial started in September 2016. 
During the first 10 weeks of the inclusion period of the trial, a total of 79 GPs from 26 
practices participated in the trial; GPs from 11 of these practices (42%) had participated 
in other studies of the EMC Department of General Practice. 22 patients were referred for 
table 1: Inclusion and Exclusion criteria for patient recruitment in the PACE Plus trial
Inclusion criteria Exclusion criteria
•  Age between 18 and 60 years;
•  Low back pain of less than 6 weeks duration;
•  Primary complaint of pain between the 12th 
rib and buttock crease;
•  Experiencing a new episode of low back pain, 
preceded by a period of at least 1 month 
without low back pain;
•  Low back pain severe enough to cause at 
least moderate pain (≥4 on 0-10 numerical 
rating scale (NRS)).
•  Known or suspected serious spinal pathology;
•  Currently taking recommended regular doses of 
analgesics, including paracetamol or diclofenac;
•  Spinal surgery within the preceding 6 months;
•  Serious comorbidities preventing prescription of 
paracetamol or diclofenac;
•  Use of medication interacting with paracetamol or 
diclofenac;
•  Known intolerance for paracetamol or diclofenac;
•  Pregnancy or planning to become pregnant during 
the treatment period.
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participation in the trial by a total number of 12 practices. Four out of these 22 patients 
(18%) could be included in the trial. 18 out of 22 (82%) referred patients were excluded; 
nine patients did not meet inclusion criteria, nine patients declined to participate in the 
trial after being informed by a research assistant over the phone. Reasons why referred 
patients did not meet inclusion criteria are presented in Table 2. Shortly after inclusion, 
the first included patient declined further participation and was lost to follow-up.
In November 2016, the trial was temporarily suspended due to insufficient patient re-
cruitment and the ‘Advice only’-group was removed from the design after approval from 
the Medical Research and Ethics Committee (MREC) of the Erasmus MC and the funding 
party (ZonMw), because a majority of participating GPs reported that their patients with 
LBP did not accept the 25% chance of receiving no medication whatsoever. The ‘Advice 
only’-group was perceived by many patients as well as participating GPs as doing nothing. 
As a result of the design modification, two of the four included patients were censored 
from the trial because they had been randomized to the ‘Advice-only group’.
After the design modification, a total of 96 GPs from 36 practices participated in the 
trial; GPs from 13 of these practices (36%) had participated in other studies of the EMC 
Department of General Practice. Nine more patients were referred for participation in 
the trial by a total number of six practices. None of the nine patients could be included in 
the trial; four patients did not meet inclusion criteria and five patients declined participa-
tion after being informed over the phone by a research assistant.
table 2: Patient referral and inclusion and exclusion in the PACE Plus trial
Trial period Before design 
modification
After design 
modification
Total
number of participating GPs
(number of participating practices)
79
(26)
96
(36)
96
(36)
referrals (number of referring practices) 22 (12) 9 (6) 31 (15)
exclusions (% of referrals) 18 (82%) 9 (100%) 27 (87%)
Patient did not meet inclusion criteria 9 4 13
Intake of study medicines before inclusion 5 1 6
Pain score (NRS 0-10) <3 1 1 2
Specific cause of low back pain 0 1 1
Age > 60 years 1 0 1
Comorbidity/co-medication with interaction 1 1 2
Insufficient knowledge of Dutch language 1 0 1
Patient declined to participate 9 5 14
Inclusions (% of referrals) 4 (18%) 0 (0%) 4 (13%)
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Because insufficient numbers of patients could be included despite the study design 
modification, the PACE Plus trial was terminated in February 2017, approximately six 
months after the start of recruitment. To investigate the underlying reasons for termina-
tion of this RCT, GPs from all participating practices were sent a survey. This publication 
has two aims: firstly, to provide transparent communication about our unsuccessful 
patient recruitment, including results from the GP survey and secondly, to make recom-
mendations for future researchers in this field of study in order to avoid the problems 
encountered in this trial.
MethodS
After the PACE Plus trial was discontinued, a letter explaining the trial had been termi-
nated because of insufficient patient recruitment was sent to all local research collabora-
tors (one GP for each participating practice, n = 36). Attached to this letter was a form 
with 3 blank answer boxes and a single question: “In your opinion, what are the (3) most 
important reasons why patient recruitment failed?”. GPs were requested to return their 
answer to this question in a pre-paid envelope that was provided. Reminders were sent 
two months and three months after the original letter to GPs who had not yet responded 
to the survey.
MS extracted all responses into Microsoft Excel 2010 as individual reasons. BK, PL and 
MS created 3 reason categories: patient factors (i.e. factors related to patient expecta-
tions and coping mechanisms), GP factors (i.e. factors related to presentation of patients 
in clinical practice and organization of care) and Research factors (i.e. factors related 
to trial design and organization). PL and MS categorized all reasons into one of these 
categories. MS computed percentages using Microsoft Excel 2010 and interpreted initial 
results. BK and PL checked these computations and interpretation. For categories with 
a minimum of 8 responses (10% of total reasons), BK and MS selected quotes that rep-
resented the opinions of multiple GPs for that specific category. Quotes were translated 
from Dutch to English by BK and MS.
reSuLtS
26 out of 36 GPs responded to the survey after the first letter (19 returned the original 
filled-out form by post, seven sent an e-mail with their opinion). Six out of the remaining 
10 GPs responded after the first reminder (four by post, two by e-mail). After a final 
reminder, one of the remaining four GPs responded to the question by e-mail. In total, 
33 out of 36 practices (94%) sent a response. Not all respondents sent back exactly 
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three factors, this ranged from one to four factors per response. Responses were usually 
formulated as short sentences. A total of 81 factors were reported (Table 3). These have 
been categorized into patient factors (26 out of 81 comments, 32%), GP factors (39 out 
of 81 comments, 48%) and research factors (16 out of 81 comments, 20%).
Most of the comments about patient factors stated that patients had other expecta-
tions when seeking care for LBP than participating in a trial (14 out of 26 comments). 
Examples of these expectations from the survey were patients asking either for alterna-
tives for paracetamol or for stronger pain medication than NSAIDs and patients request-
ing further diagnostics by x-ray. One GP wrote: “The study went against expectations of 
patients and doctors. The idea not to take or prescribe pain medication when someone is 
in pain requires abstract reasoning. GPs aren’t happy to dismiss paracetamol, too much 
time was invested to promote the usefulness of this drug. This means there is a lose-lose 
situation; both the patient and the GP lose in this trial (at least from a superficial point 
of view)”. Other patient factors mentioned by GPs were that patients felt confident they 
could self-manage their LBPs (using validated online patient information such as the 
patient information website of the Dutch College of General Practitioners (NHG) (5) or 
using direct access to physiotherapy, seven out of 26 comments) and patients declining 
participation in the trial directly in the practice (five out of 26 comments).
table 3: Results of survey amongst 33 participating GPs
GP opinions on why recruitment failed in the PACE Plus trial Total number of comments
(% of total comments)
1. Patient factors: 26 (32%)
1.1 Patient had other expectations when seeking care for low back pain 14
1.2 Patients were confident they could self-manage their low back pain 7
1.3 Patient declined participation 5
2. GP factors: 39 (48%)
2.1 Insufficient number of patients meeting criteria were seen in practice or 
spoken to on the telephone
20
2.2 Lack of time or trial forgotten because of other tasks 14
2.3 The trial had just started or had not yet started in the practice 3
2.4 Not all employees of the practice were sufficiently informed about the trial 2
3. Research factors: 16 (20%)
3.1 Medication distribution procedure too complicated 7
3.2 Research question and design irrelevant for clinical practice 4
3.3 Inclusion and exclusion criteria too restrictive 2
3.4 Research logistics disturb usual clinical care 2
3.5 Problems in communication with research department 1
Total number of comments from 33 GPs: 81 (100%)
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Nearly a quarter of all comments mentioned insufficient numbers of patients meeting 
the inclusion criteria for the PACE Plus trial presenting in the practice or on the phone 
(20 comments). The quote best capturing this stated: “I personally see few people in 
my practice that meet the inclusion criteria. Age, duration of complaints, etcetera. The 
GP’s assistant solves a lot of cases; those patients could otherwise have participated in 
the trial”. Another reason that was often stated was lack of time due to patient care and 
administration tasks (14 comments). Several GPs mentioned forgetting about the trial be-
cause of the high workload; one respondent wrote: “It’s very hectic! I only remembered 
to ask my patient to participate after he’d already left”. Other GP factors considered 
organizational issues in the GP practices: two GPs stated that not all employees in the 
practice were sufficiently informed about the trial, three GPs had only just or not yet 
started participating in the trial.
Research factors reported could be related to both study design choices and trial 
organization by the research department. Apart from the GPs mentioning insufficient 
numbers of patients presenting in their practice, two GPs explicitly stated that inclusion 
and exclusion criteria were too restrictive to be realistic. Seven GPs found the medication 
distribution procedure too complicated and the subsequent time delay before the patient 
received medication unacceptable. Four GPs believed the trial research question was 
irrelevant for clinical practice. Two GPs stated that the trial design caused disturbance 
of usual clinical care. Finally, one GP mentioned that communication with the research 
department was not clear enough.
diScuSSion
Termination of the PACE Plus trial may be attributable to research logistics and design, 
patient related and GP related factors. We will discuss these factors considering the 
survey described above as well as reflecting on design choices made in this trial’s pre-
decessor, the PACE trial, which did manage to successfully recruit 1650 patients with 
comparable complaints.
In retrospect, an important weakness in the logistics of PACE Plus was the compli-
cated medication distribution procedure, as mentioned by several GPs in the survey. 
Patients could only be randomized once informed consent was signed and the baseline 
questionnaire had been filled out; very often, patients could not find the time to do this 
immediately after referral, which meant randomization and preparation of a medication 
pack would be delayed. As GP practices participating in the trial were spread across 
three Dutch provinces, 24-hour postal delivery was used to get medication packs to 
participants. In practice, this meant that patients who were in pain had to wait at least 
24 to 48 hours before receiving medication; in contrast, if patients declined to participate 
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in the trial and asked their GP for a prescription, they would usually be able to pick 
up pain medication at their local pharmacy within an hour. Alternatively, patients could 
buy paracetamol and NSAIDs as over-the-counter medication without a prescription. 
Although our medication distribution procedure did fit within the limitations of Dutch 
law on medical research in humans, we have underestimated the potential for delay 
to arise in practice, the discomfort this meant for the participants and the unfavorable 
position of the trial in comparison to conventional treatment options.
During the design phase of PACE Plus, an alternative medication distribution procedure 
was considered. In this scenario, GPs would be asked to inform patients about the trial, 
collect informed consent, randomize patients and give them a medication pack immedi-
ately. However, under Dutch law on medical research in humans, this meant medication 
packs would have to be stored in a locked, temperature controlled environment, for which 
extra records would have to be kept by participating GPs. Although this scenario more 
closely resembled clinical practice and diminished delay, the procedure was dismissed 
because it would ask a substantially larger investment of time of participating GPs (who 
were already on a very tight schedule) and would require purchasing special medication 
storage equipment for all participating practices, for which trial budget did not allow.
Apart from logistics, alternative target populations were also considered during design 
of the trial. We chose to recruit patients with a new episode of acute LBP (incident 
cases) as opposed to prevalent cases of acute LBP (less than 6 weeks of pain) for two 
reasons. Firstly, our main aim was to replicate the PACE trial, which used incident cases. 
Secondly, many patients with prevalent LBP would already be using recommended doses 
of paracetamol or NSAIDs and would therefore be ineligible for participation in the trial. 
A more feasible alternative might have been to recruit patients with chronic LBP, but 
this of course would mean investigating a completely different research question and a 
design with a much longer follow-up period. Therefore, although more challenging than 
the alternatives, recruitment of incident cases of acute LBP seemed the most appropri-
ate choice considering the aim of our trial. The discontinuation of this trial supports the 
previous finding that recruiting incident cases during the GP’s consultation is associated 
with a lower probability of complete and timely patient recruitment (6). For future re-
search, other designs such as an RCT embedded in a cohort of patients with recurrent 
LBP could be considered as an alternative to recruitment of incident cases during the 
first consultation.
Another design choice that may have impacted the feasibility of this trial was the 
objective to both repeat PACE and explore the alternatives to paracetamol in one trial. 
Not only did this mean that double the number of patients had to be recruited than 
when comparing just paracetamol and placebo, it also meant that the trial was more 
complicated to explain to both participating GPs and eligible patients. In hindsight, it 
might have been better to focus on one of our objectives and design the trial accordingly.
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In terms of patient factors, effective self-management of LBP may have had an impact 
on patient recruitment. This is supported by the fact that the most important reason 
for exclusion during PACE Plus was patients already taking one of the study medicines; 
furthermore, several GPs mentioned in the survey their patients were confident they 
could self-manage their LBP. Several societal developments could have contributed to 
this improved self-management. Firstly, since 2006, patients have access to physiother-
apy without referral from a GP, although research suggests this does not influence the 
number of GP visits (7). Secondly, it was demonstrated that the introduction of a patient 
information website of the NHG (5) has led to a decrease in healthcare usage of 12% (8). 
Finally, both paracetamol and NSAIDs are available without a doctor’s prescription, as 
they are registered as over-the-counter medications in the Netherlands.
In PACE Plus, 14 of 27 excluded patients declined to participate in the trial. This is 
highly related to the comments of GPs that patients had other expectations and that 
patients declined participation. The trial did not provide any new treatment or in fact, 
any intervention that the patient could not obtain over-the-counter as mentioned above; 
instead, it relied on altruism of patients to answer the research question. The reason 
why patients declined to participate may have been because the underlying problem 
and research question were not considered relevant enough by many patients, as was 
mentioned in the survey by four GPs. This may have been avoided by discussing research 
ideas with a group of acute low back pain patients and taking their specific preferences 
and expectations for both treatments and outcomes into consideration.
Lack of GP’s time was often mentioned as a factor affecting patient recruitment. This 
statement appears to reflect recent trends in increasing workload for Dutch GPs because 
of changes in the national health care system (9). As a result of this increasing workload, 
less time is available for participating in clinical research, which affects the feasibility of 
conducting clinical trials in general practice (10).
GPs participating in the PACE Plus trial reported a lower incidence of acute LBP than 
was initially expected based on incidence figures reported in the NHG practice guideline 
(11). This may have been because of Lasagna’s law(6, 12, 13), the phenomenon that re-
searchers overestimate the number of available patients meeting inclusion and exclusion 
criteria of a trial (originally formulated as “the incidence of patient availability sharply 
decreases when a clinical trial begins”).
Considering PACE Plus investigated a highly similar patient group and similar interven-
tions to the original PACE trial, we looked into differences between the two studies that 
may explain why PACE successfully completed patient recruitment while PACE Plus failed 
to do so. Firstly, the total budget in the PACE trial was substantially higher than in PACE 
Plus, which meant that in PACE, three fulltime research assistants could be employed as 
opposed to 1.2 fulltime equivalent in PACE Plus. Furthermore, both GP’s and participants 
could be reimbursed for their time invested in the trial in PACE, whereas there was no 
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compensation in PACE Plus. Other strategies used in PACE but omitted in PACE Plus in-
cluded conducting a pilot trial and rewarding participating GPs with Mandatory Continu-
ing Education (MCE) points. In PACE, a ‘novel’ treatment (modified release paracetamol) 
was investigated that could potentially have been added to conventional treatment 
options, whereas in PACE Plus, two of the treatments were somewhat controversial both 
for GPs and patients (diclofenac and no medication); additionally, some GPs feared los-
ing paracetamol as a treatment option. Finally, as opposed to the complex medication 
distribution procedure used in PACE Plus, medication was allowed to be directly provided 
by the GP preventing delay in patients commencing their pain relief medicine.
concLuSion
Although the PACE Plus trial was terminated as a result of insufficient patient inclusion, 
the research questions addressed in this trial remain relevant but unanswered. This is 
especially true in light of recent international LBP guidelines (14-17), in which the use 
of any medication for LBP is discouraged. Lessons learned from the discontinuation of 
PACE Plus and corresponding recommendations have been summarized in Table 4. We 
hope that these lessons and recommendations may be helpful in the design of upcoming 
research projects in LBP in general practice.
table 4: Lessons learned from discontinuation of the PACE Plus trial and corresponding recommenda-
tions for future research
Lessons learned Recommendations for future research
•  Even though treatment distribution follows 
legislation and works on paper, they may have 
issues in practice that affect patients.
•  Asking GPs to recruit incident cases during the 
first consultation seems unlikely to be successful 
considering the current workload in general 
practice.
•  Attempting to answer several research questions 
at once not only requires more patients but is 
also more complicated to explain to GPs and 
potential participants.
•  Interests and expectations of patients can 
collide with scientifically interesting questions in 
practice.
•  The number of available patients meeting 
inclusion criteria is easily overestimated 
(Lasagna’s Law).
•  Negative perception of trial treatment may 
influence participation of both GPs and patients.
•  Keep treatment distribution as simple as 
possible and provide an attractive alternative to 
conventional therapy.
•  Try to answer your research question in 
prevalent cases or use alternative designs such 
as a trial within a cohort study. Take into account 
reimbursement of GPs in grant application and 
budgeting (especially if you do end up recruiting 
incident cases).
•  Choose your most important research question 
and design your trial to be as simple as possible.
•  Before starting a trial, ask a patient panel 
for their preferences and expectations of 
treatments and outcomes. Ask GPs if they 
know of any reservations about treatments you 
consider using.
•  Take Lasagna’s law into account when planning 
your trial.
•  Consider conducting a pilot trial and taking part 
in Mandatory Continuous Education.
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ABStrAct
Introduction
The aim of this study was to reanalyze and reinterpret data obtained in PACE, the first 
large randomized controlled trial evaluating the efficacy of paracetamol in acute low back 
pain, to assess the inferential reproducibility or the original conclusions.
Methods
Mixed effects models were used to reanalyze pain intensity (primary outcome; 11-point 
Numeric Rating Scale), and physical functioning, health-related quality of life, sleep qual-
ity and time until recovery (as secondary outcomes), according to the intention-to-treat 
principle. The original authors of the PACE study were not involved in the development 
of the methods for this reanalysis.
results
The reproduction analyses indicated no effect of treatment on pain intensity and confi-
dence intervals excluded clinically worthwhile effects (coefficient for regular paracetamol 
versus placebo 0.00 (-0.02 - 0.01, p = 0.85); coefficient for paracetamol as-needed versus 
placebo 0.00 (-0.02 – 0.01, p = 0.92)). Similar results were obtained for all secondary 
outcomes.
conclusions
This study indicates that the conclusions of the PACE trial are inferentially reproducible, 
even when using a different analytical approach. This reinforces the notion that manage-
ment of acute low back pain should focus on providing patients advice and reassurance 
without the addition of paracetamol.
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ABStrAct
Introduction
In 2014, the PACE trial demonstrated that paracetamol had no effect compared to pla-
cebo in acute low back pain (LBP). However, non-compliance was a potential limitation 
of this trial. The aim of this study was to investigate the efficacy of paracetamol in acute 
low back pain among compliers.
Methods
Using individual participant data from the PACE trial (ACTN12609000966291), Complier 
Average Causal Effects (CACE), Intention-to-treat (ITT) and Per Protocol (PP) estimates 
were calculated for pain intensity (primary), and disability, global rating of symptom 
change and function (all secondary) after two weeks of follow-up. Compliance was 
defined as intake of an average of at least four of the prescribed six tablets of regular 
paracetamol per day (2660 milligrams in total) during the first two weeks after enrol-
ment. Exploratory analyses using alternative time points and definitions of compliance 
were conducted.
results
Mean between-group differences in pain intensity on a 0-10 scale using the primary 
time point and definition of compliance were not clinically relevant (propensity weighted 
CACE 0.07 (-0.37, 0.50) p = 0.76; joint modelling CACE 0.23 (-0.16, 0.62) p = 0.24; ITT 0.11 
(-0.20, 0.42) p = 0.49; PP 0.29 (-0.07, 0.65) p = 0.12); results for secondary outcomes and 
for exploratory analyses were similar.
conclusions
Paracetamol is ineffective for acute low back pain even for patients who comply with 
treatment. This reinforces the notion that management of acute low back pain should 
focus on providing patients advice and reassurance without the addition of paracetamol.
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introduction
The Paracetamol for Acute Low Back Pain (PACE) trial was the first placebo-controlled ran-
domized controlled trial (RCT) investigating the efficacy of paracetamol (acetaminophen) 
for acute low back pain (LBP) (1-3). In this RCT, 1652 people seeking care for LBP were 
randomized to take paracetamol regularly, paracetamol as needed for pain, or placebo 
using a blinded double-dummy design. The unexpected result that paracetamol had no 
effect compared to placebo on pain intensity, time until recovery, disability and function 
in acute LBP received worldwide attention in the medical literature and the lay-press. 
Nonadherence to study medication was identified as a potential limitation in the original 
publication of the PACE results as well as in a number of commentaries discussing the 
impact of the trial (1, 4-6); in a descriptive analysis of nonadherence in PACE, 70% of pa-
tients were found to be non-adherent over the four-week treatment period, and overall 
adherence to guideline-recommended care for acute LBP was described as ‘poor’ (5). In 
RCTs, noncompliance has always been an issue and may even influence their results (7). 
However, the question as to whether there is benefit of an intervention in participants 
who adequately adhere to treatment is difficult to answer using conventional techniques 
used in the analysis of RCTs (i.e. intention to treat analysis and per protocol analysis).
Complier average causal effects (CACE) analysis involves comparing participants who 
were randomized to the intervention and complied, to participants from the control 
group who would have complied to the intervention had they been randomized to the 
intervention (so called ‘would be compliers’). As participants in the control group are 
never offered the active treatment in reality, there is no observed data in the control 
group for adherence to active treatment. CACE analysis is therefore essentially a missing 
data problem. CACE analyses have been used to assess the efficacy among compliers of 
intervention programs in substance abuse, behavioral interventions and a multifactorial 
intervention in physiotherapy (8-16). In the field of LBP, CACE analysis has been used 
to assess the influence of non-compliance on effectiveness of a cognitive behavioral 
intervention (17).
This analysis aims to investigate the efficacy of paracetamol in acute LBP among par-
ticipants who complied with regular paracetamol treatment in the PACE trial using a 
CACE analysis, to address the uncertainty that compliance may have influenced drug 
efficacy (14, 15). Additionally, we conducted intention to treat analysis and per protocol 
analysis to compare to the CACE analysis.
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MethodS
ethics
The University of Sydney Human Research Ethics Committee granted ethical approval 
of the PACE trial protocol. Written informed consent was provided by all participants. 
The PACE trial was registered with the Australian and New Zealand Clinical Trial Registry, 
number ACTN12609000966291.
Participants and procedures
The PACE trial was a multicenter, double-dummy, randomized, placebo-controlled trial 
that was conducted from November 2009 until March 2013. The study protocol, analysis 
plan and main outcomes have been published (1-3). In summary, 4606 people seeking 
care for acute non-specific low-back pain or responding to a community advertisement 
were screened by 235 primary care clinicians across Sydney, Australia. The trial included 
1652 participants with a new episode of moderate, or severe-intensity low back pain 
with or without leg pain. Participants were randomly allocated (in a 1:1:1 ratio) to receive 
2 tablets of 665 mg modified-release paracetamol tablets 3 times a day regularly (n = 
550), or 2 tablets of 500 mg immediate-release paracetamol tablets up to 4 times a day 
as-needed for pain (n = 549), or placebo (n = 553). Participants, clinicians and researchers 
were blinded to allocation of treatment during the trial. Participants were instructed to 
use study medication until they had experienced 7 consecutive days with pain scores of 
0 or 1 out of 10 (measured on a numerical pain rating scale (NRS)), or for a maximum of 
four weeks, whichever occurred first. Participants were asked to return to their clinician 
for review after 1 week, at which time the use of study medication was reviewed. Rescue 
medication (naproxen 250 mg) was available for participants with continuing ongoing 
pain as required.
Participants recorded pain scores and number of tablets taken in a daily pain and drug 
diary until recovery or for a maximum of four weeks. Follow-up data was collected at 1, 2, 
4 and 12 weeks after randomization. Data were either entered directly by the participant 
into an online database or recorded by participants in a booklet and transcribed to a 
case report form during a telephone interview with research staff. Returned tablets were 
counted by research staff to confirm self-reported compliance. In this CACE analysis, data 
from the as-needed treatment group were not used because the ‘need’ to take medica-
tion would have been different for each individual participant, preventing the use of one 
universal definition of compliance in this treatment group.
outcome measures
For this CACE analysis, pain intensity measured on a NRS from 0 (no pain) to 10 (worst 
possible pain) was the primary outcome; analyses were also performed for disability (Ro-
99
cAce analysis of the PAce trial
6
land Morris Disability Questionnaire, scored from 0 (no disability) to 24 (high disability)), 
Global rating of symptom change (scored from -5 (vastly worse) to +5 (completely recov-
ered)) and function (Patient Specific Function Scale, with the average of 3 items scored 
from 0 (unable to perform) to 10 (able to perform at preinjury level), these outcomes 
represent two of the three core outcome domains for non-specific LBP (18). Although 
measurements were conducted in the PACE trial for the third core outcome domain 
(health-related quality of life), this outcome was omitted from the CACE analysis because 
of missing data (the Short Form 12 (SF12)), which we expected would compromise the 
CACE estimation. Time until recovery, the primary outcome of the original PACE analysis, 
was omitted as methods for survival CACE analysis have not yet been developed.
Definitions of compliance to the study intervention and time points
Compliance was defined as taking an average of at least 4 tablets per day (approximately 
66% of the prescribed dosage or 2660 mg per day) of modified-release paracetamol until 
recovery or for a maximum of 2 weeks for the primary outcome of the CACE analysis 
(pain intensity at 2 weeks of follow-up).
Two alternative cut-off points for compliance were defined a priori to assess whether 
the treatment effect differed according to the level of compliance: taking an average of 5 
tablets per day (83% of the prescribed dosage or 3325 mg per day) and taking 6 tablets 
per day (100% of the prescribed dosage or 3990 mg per day). The two-week question-
naire was chosen as the primary time point as this was closest to the median recovery 
time (1); exploratory analyses were performed at 1 week and 4 weeks follow-up for pain 
intensity only. For the exploratory analysis of pain intensity at 4 weeks, the definition of 
compliance was expanded to ‘until recovery or for a maximum of 4 weeks’.
Statistical analysis
Using individual participant data from the PACE trial, baseline participant and back pain 
episode characteristics were compared between observed compliers and observed non-
compliers in the regular paracetamol treatment group, using standardized differences 
(St.Diffs). For binary variables, the St.Diff was calculated as the difference in proportions 
divided by the standard deviation i.e. (p1 – p2) / sqrt ( [ p1 ( 1 – p1) + p2 ( 1 – p2) ] / 2). 
For categorical variables with more than 2 levels, we used a method proposed by Yang 
and Dalton based on a multivariate Mahalanobis distance method which generalizes 
the St.Diff metric (19). St.Diffs larger than 0.1 were considered to be relevant and were 
reported in the results section.
We calculated ITT, CACE and Per Protocol (PP) estimates for the 4 outcomes of interest 
(pain intensity, disability, global rating of symptom change, and function). ITT analyses 
were performed consistent with the original analysis of the PACE trial, comparing 
outcomes between all participants randomized to the regular paracetamol group and 
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all patients randomized to the placebo group using linear mixed models adjusted for 
all baseline characteristics (1, 3). Based on our definition of compliance, we created a 
dichotomous variable indicating observed compliance status. We used this dichotomous 
variable for the PP analysis, where we compared outcomes of observed compliers from 
the regular paracetamol group to outcomes of observed compliers in the placebo group 
using linear mixed models adjusted for all baseline characteristics. Outcomes of the PP 
analysis are not included in the main results of this article, but are added to the supple-
mentary information. The reason for this is that we were interested in comparing results 
of the CACE analysis to results of a PP analysis, which may provide biased estimates 
of efficacy for compliers, as the reasons for noncompliance could be different for the 
regular paracetamol group than for the placebo group. For example, noncompliance in 
the regular paracetamol group could be related to side effects despite efficacy, whereas 
noncompliance in the placebo group may be due to lack of efficacy (20). In the Supple-
mentary Information, the difference between PP and CACE analyses is discussed in more 
detail.
As the underlying assumptions for CACE analysis are untestable, we obtained CACE 
estimates using both a propensity weighted estimation approach and a joint modeling 
estimation approach, which serve as each other’s sensitivity analysis (15). More informa-
tion about the underlying assumptions for these CACE estimation techniques can be 
found in the Supplementary Information. For the propensity weighted CACE estimation, 
compliance to regular paracetamol was predicted on baseline covariates using logistic 
regression with a dichotomous variable indicating the observed compliance status. The 
prediction model was developed using only data from the regular paracetamol group. 
This model was then used to calculate the likelihood of compliance (propensity score) in 
the placebo group. To prevent missing propensity scores due to missing baseline data, 
missing baseline variables were imputed once using fully conditional specification (i.e. 
imputation on a variable-by-variable basis in an iterative fashion, with an imputation 
model specified for each incomplete baseline variable (21)). The imputed dataset was 
used to predict the propensity score. Once derived, the propensity scores were added 
back to the original non-imputed baseline data set and each participant was weighted as 
follows: in the regular paracetamol treatment arm, compliers received a weight of 1 and 
non-compliers a weight of 0; in the placebo treatment arm, the weight was calculated 
as the odds of the propensity score p (odds=p/(1-p)). We investigated if any residual 
imbalances existed after weighting by calculating St.Diffs between baseline variables 
between compliers in the regular paracetamol group and weighted placebo group par-
ticipants (see Supplementary Information). Finally, we performed an analysis comparing 
compliers in the regular paracetamol group to odds-weighted patients in the placebo 
group. Propensity weighted CACE analyses were adjusted for all baseline characteristics 
in order to correct for residual imbalances. To assess a potential “dose-response” ef-
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fect we performed a pre-specified subgroup analysis according to quintiles of likelihood 
of compliance (using the propensity scores created for the propensity weighted CACE 
analysis). For this subgroup analysis, the primary cut-off point for compliance (taking an 
average of at least 4 tablets of modified-release paracetamol per day) and primary time 
point (two weeks of follow-up) were used); for each quintile group, a mean difference 
and corresponding confidence interval was calculated.
For the CACE analysis using joint modeling, 2 models were simultaneously estimated: 
a model for compliance and a model for the outcome (pain intensity). Estimates were 
adjusted for all baseline characteristics. This estimation approach resulted in a compari-
son between observed compliers in the regular paracetamol group to inferred compliers 
(would-be-compliers) in the placebo group.
Results of all the analyses (ITT, CACE propensity and CACE joint modeling and PP) are 
presented as mean differences between paracetamol and placebo groups with 95% 
confidence intervals and corresponding p-values. ITT, PP and propensity weighted CACE 
analyses were performed in SAS version 9.4 (SAS Institute, Inc., Cary, NC), joint modeling 
CACE estimation was performed in Mplus version 7 (22).
reSuLtS
characteristics of compliers to regular paracetamol
The baseline characteristics of participants in the regular paracetamol group are present-
ed in Table 1; participants were split into compliers and non-compliers based on our main 
definition of compliance (an average of at least 4 tablets of 665 mg regular paracetamol 
per day during the first 2 weeks). Table 1 also shows St.Diffs between observed compliers 
and non-compliers. At the primary time point of the CACE analysis (2 weeks), 394 out of 
550 participants in the paracetamol group (72%) were classified as compliers.
When comparing compliers and non-compliers, compliers tended to be somewhat 
older (44.9 vs 42.4 years, St.Diff 0.17); were more likely to be male (54% vs 46%, St.Diff 
0.15); were more likely to have private health insurance (52% vs 46%, St.Diff 0.12); had 
a different distribution of household income (St.Diff 0.23); were less likely to have pain 
extending beyond the knee (17% vs 26%, St.Diff 0.22); had a longer period of reduced 
usual activity (4.1 vs 3.2 days, St.Diff 0.13); scored higher for feelings of depression (3.4 
vs 2.8, St.Diff 0.18); reported a higher perceived risk of persistent pain (4.8 vs 4.1 out of 
10, St.Diff0.22); more often reported poor sleep quality (51% vs 46%, St.Diff 0.10); scored 
lower on function (3.4 vs 3.7, St.Diff 0.15) and scored lower for physical quality of life 
(42.4 vs 43.3, St.Diff 0.11).
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table 1: Baseline characteristics for observed compliers and non-compliers in the regular paracetamol 
group, including standardized mean differences between observed compliers and observed non-com-
pliers.
Patient characteristics Regular Paracetamol (N = 550) Standardized
differencesObserved
compliers
(N = 394)
Observed
non-compliers
(N = 142)
Age (years) 44.9 (14.9) N = 394 42.4 (14.5) N = 142 0.171*
Women 182/393 (46%) 75/140 (54%) 0.146*
Private health insurance 203/394 (52%) 65/142 (46%) 0.115*
Currently employed 305/394 (77%) 107/142 (75%) 0.048
Household income per week (per year) 0.342*
Negative or no income 13/384 (3%) 6/142 (4%)
AUD 1-649 (1-33799) 89/384 (23%) 42/142 (30%)
AUD 650-1699 (33800-88399) 174/384 (45%) 59/142 (42%)
AUD 1700-3999 (88400-207999) 86/384 (22.4%) 32/142 (23%)
≥AUD 4000 (≥208000) 22/384 (6%) 3/142 (2%)
Use of drugs for another disorder 148/394 (38%) 49/142 (35%) 0.064
LBP Episode characteristics
Days since onset of pain 10.2 (10.3) N = 394 9.8 (9.6) N = 142 0.037
Number of previous episodes 6.4 (12.8) N = 392 6.5 (16.4) N = 141 0.009
Presence of pain extending beyond the knee 68/392 (17%) 37/141 (26%) 0.217*
Number of days reduced usual activity 4.1 (7.0) N = 393 3.2 (4.9) N = 141 0.134*
Disability (RMDQ) 12.7 (5.5) N = 390 12.9 (5.9) N = 139 0.027
Feelings of depression in last week 3.4 (2.9) N = 392 2.8 (3.0) N = 141 0.175*
Perceived risk of persistent pain 4.8 (2.7) N = 392 4.1 (2.9) N = 142 0.224*
Back pain episode compensable 20/392 (5%) 10/140 (7%) 0.085
Pain intensity (NRS) 6.3 (1.9) N = 394 6.2 (2.0) N = 142 0.039
Global rating of symptom change 0.0 (2.1) N = 393 0.1 (2.0) N = 141 0.054
Poor sleep quality 200/393 (51%) 65/142 (46%) 0.103*
Function (Nominated Activity) 3.4 (1.7) N = 392 3.7 (1.9) N = 141 0.151*
Quality of life – physical (SF-12) 42.4 (9.0) N = 384 43.3 (9.4) N = 140 0.112*
Quality of life – mental (SF-12) 44.3 (7.7) N = 384 43.7 (7.8) N = 140 0.071
Credibility score (CEQ) 19.1 (4.9) N = 390 18.8 (4.8) N = 140 0.064
Expectation score (CEQ) 19.8 (5.4) N = 389 19.4 (5.3) N = 141 0.080
St.Diffs: Standardized Differences; Data are mean (SD) or n/N (%);* under standardized differences in-
dicate St.Diffs > 0.1. AUD: Australian Dollar; LBP: Low Back Pain; NRS: Numerical Rating Scale; RMDQ: 
Roland Morris Disability Questionnaire; SF-12; 12-item Short Form Survey; CEQ: Credibility/Expectancy 
Questionnaire.
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estimates of the cace models
Table 2 presents ITT and CACE estimates for pain intensity, disability, global rating of 
symptom change, and function in the PACE trial at week 2 with compliance defined as an 
average intake of at least 4 tablets per day during the first 2 weeks.
For the primary outcome measure, none of the analyses indicated a difference in pain 
intensity (ITT: mean difference 0.11 (-0.20, 0.42) p = 0.49; joint modeling CACE: mean 
difference 0.23 (-0.16, 0.62) p = 0.24; propensity weighted CACE: mean difference 0.07 
(-0.37, 0.50) p = 0.76). Similar results were obtained for the secondary outcomes dis-
ability, global rating of symptom change, and function. Confidence intervals of estimates 
for pain intensity, global rating of symptom change and function were all between -1 and 
1 and therefore exclude clinically meaningful differences; the confidence interval of the 
estimate of disability exceeded 1 in both the propensity weighted CACE estimation and 
the joint modelling CACE estimation; however, this difference is still smaller than the 
minimal clinically important difference (MCID) of 30% change from baseline (in PACE, 
approximately 4 points) (23).
table 2: Outcomes of PACE trial (Pain Intensity, Disability, Global Rating of Symptom Change and 
Function) at week 2 with compliance defined as an average intake of ≥4 tablets per day for regular 
paracetamol group vs placebo group.
Outcome ITT Propensity weighted
CACE
Joint Modeling
CACE
Pain Intensity (NRS)
(scale range 0-10)
0.11 (-0.20, 0.42)
p = 0.49
0.068 (-0.37, 0.50)
p = 0.76
0.23 (-0.16, 0.62)
p = 0.24
Disability (RMDQ)
(scale range 0-24)
0.11 (-0.60, 0.82)
p = 0.76
0.054 (-0.93, 1.04)
p = 0.91
0.37 (-0.55, 1.30)
p = 0.43
Global Rating of Symptom Change
(scale range -5 to +5)
0.0019 (-0.26, 0.27)
p = 0.99
0.059 (-0.33, 0.44)
p = 0.76
-0.083 (-0.42, 0.25)
p = 0.62
Function (Patient Specific Function Scale)
(scale range 0-10)
-0.069 (-0.38, 0.24)
p = 0.67
0.0043 (-0.45, 0.45)
p = 0.99
-0.28 (-0.67, 0.11)
p = 0.16
All values represent mean difference (lower limit of 95% CI, upper limit of 95% CI) p value; mean differ-
ences calculated by subtracting placebo group mean from regular paracetamol group mean. All analyses 
were adjusted for gender and baseline age, private health insurance, employment status, household 
income, use of drugs for another disorder, days since onset of pain, number of previous episodes, pres-
ence of pain extending beyond the knee, number of days reduced usual activity, disability (RMDQ), feel-
ings of depression, perceived risk of persistent pain, back pain episode compensability, pain intensity, 
global rating of symptom change, sleep quality, function, quality of life (mental and physical components 
of the 12 item short form survey (SF-12)) and credibility and expectation scores (CEQ). Values rounded to 
2 significant figures. Abbreviations: CACE: Complier Average Causal Effect; CEQ: Credibility/Expectancy 
Questionnaire; ITT: Intention-to-Treat; NRS: Numerical Rating Scale; RMDQ: Roland Morris Disability 
Questionnaire.
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figure 1: Exploratory ITT and CACE analyses for pain intensity including both primary and alternative 
cut-off points for compliance (an average of at least 5 tablets per day and 6 tablets per day, calculated 
over the periods of interest) as well as primary and alternative time points (1 week and 4 weeks). Val-
ues rounded to 2 significant figures. ITT: intention to treat, CACE: Complier Average Causal Effect, CI: 
Confidence Interval.
105
cAce analysis of the PAce trial
6
exploratory analyses
Figure 1 shows results of the exploratory ITT and CACE analyses using primary and 
alternati ve cut-off  points for compliance (an average of at least 5 tablets per day, and 
6 tablets per day) and primary and alternati ve ti me points (1 week and 4 weeks). Mean 
diff erences in pain intensity between regular paracetamol and placebo were calculated 
for 3 defi niti ons of compliance at 3 ti me points using 3 analysis techniques, yielding a 
total of 21 esti mates.
Minimal diff erences in pain intensity were only found for 2 of the 21 analyses: the 
joint modeling CACE esti mate aft er 2 weeks with compliance defi ned as an average of 
at least 5 paracetamol tablets per day (mean diff erence 0.45 (0.02, 0.88), p = 0.039) and 
for the propensity weighted CACE esti mate aft er 2 weeks with compliance defi ned as 
6 paracetamol tablets per day (mean diff erence 0.41 (0.00, 0.82) p = 0.049); however, 
no correcti on was made for multi ple testi ng. Furthermore, the confi dence intervals for 
these esti mates do not include clinically meaningful diff erences. For all other ti me points, 
no diff erences in pain intensity were found.
Results of the ITT analysis for pain intensity at 2 weeks for quinti les of compliance 
(defi ned as an average of at least 4 tablets per day over 2 weeks) are depicted in Figure 2. 
No diff erence in pain intensity was found between regular paracetamol and placebo for 
any of the compliance subgroups. There appears to be no clear dose-response relati on-
ship between compliance and eff ect of paracetamol.
figure 2: Exploratory ITT analysis for pain intensity at 2 weeks for quinti les of likelihood of compliance 
(with compliance defi ned as taking an average of at least 4 tablets of modifi ed-release paracetamol per 
day during 2 weeks of follow-up). Quinti le groups are presented in order of increasing likelihood of be-
ing compliant, with Quinti le 1 representi ng the group that was least likely to be compliant and Quinti le 
5 representi ng the group that was most likely to be compliant. ITT: intenti on to treat, CI: Confi dence 
Interval.
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diScuSSion
In this secondary analysis of the PACE trial we found that paracetamol had no clinically-
meaningful effect when compared to placebo on pain intensity, disability, global rating 
of symptom change and function in people with acute LBP who complied with regular 
paracetamol.
The CACE analysis technique produces robust estimates of efficacy amongst compliers; 
furthermore, we applied 2 distinct methods to estimate complier average causal effects, 
which serve as each other’s sensitivity analysis (15). The credibility of our findings is sup-
ported by the fact that no large differences exist between these 2 estimation techniques 
(15). Data used in this analysis were collected in a large and well-conducted RCT (1, 24).
The CACE analysis technique has two main weaknesses. First, no universally accepted 
definition of compliance to paracetamol for low back pain exists. Using our main defini-
tion of compliance, 72% of participants in the regular paracetamol group were classified 
as compliers. We explored stricter definitions of compliance and found results consistent 
with the primary analysis; however, as the percentage of compliers was lower using 
these definitions, CACE estimates using these definitions are less robust. Second, CACE 
estimates were based on patient-reported compliance filled out in paper drug diaries, 
which may not have perfectly represented actual consumption of tablets. However, 
counts of returned medicines and results from the brief adherence rating scale were 
consistent with patient-reported compliance (1).
The findings of this secondary analysis should be placed in context of the original 
analysis of the PACE trial, which is still the only RCT that has assessed the efficacy of 
paracetamol for acute LBP and is considered to be the best available evidence (24). As 
mentioned in the introduction, non-compliance to study medication was considered a 
potential limitation of the PACE results (1, 4-6). The results of this analysis suggest this is 
not the case and thus support the conclusion from the original analysis of the PACE trial 
that paracetamol is ineffective for acute LBP when compared to placebo. It is important 
to note that CACE analysis is a technique that accounts for a very specific participant 
group, namely those who comply with treatment. Although this analysis technique may 
be useful in trials where non-compliance is an issue, results of the ITT analysis remain the 
most relevant to clinical practice.
After a lack of efficacy of paracetamol for acute LBP was demonstrated by the PACE 
trial, paracetamol was no longer recommended as first choice analgesic in four out of 
eight recently published national clinical practice guidelines (25-28). However, other 
recent guidelines still endorse the prescription of paracetamol for acute LBP (29-32). 
One possible justification was that paracetamol may be effective in those who comply 
with the dosing regimen. Our CACE analyses have demonstrated that the efficacy of 
paracetamol is unlikely to change even in patients with total compliance to the regular 
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regimen, reinforcing that management of acute low back pain should focus on providing 
patients advice and reassurance without the addition of paracetamol.
In conclusion, paracetamol is not more effective than placebo for acute LBP in com-
pliers of the treatment regimen. CACE analyses using different cut points showed that 
paracetamol had no effect on pain intensity and secondary outcomes when compared 
to placebo for participants that complied to regular paracetamol in the PACE trial. These 
results support the original findings of the PACE trial.
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APPendiX 1: SuPPLeMentAry inforMAtion
Background to complier average causal effect (cace) analysis
Conventional Intention-to-Treat (ITT) analysis produces the overall mean effect for all 
participants randomized, regardless of compliance status. While an ITT analysis provides 
an unbiased estimate of the effect of treatment allocation, it does not estimate the 
efficacy of treatment in compliers. Common analysis strategies used to estimate treat-
ment effect in compliers are Per Protocol (PP) analysis, where effects for compliers in 
the intervention group are compared to effects for participants in the control group, 
and As-treated (AT) analysis, where effects for those who received the intervention are 
compared to effects for those who did not receive the intervention. However, the use 
of PP and AT analyses to account for compliance may lead to biased results (1). The 
reason for this is that likelihood of compliance to placebo is fundamentally different from 
likelihood of compliance to an active treatment; this could actually work in two direc-
tions: participants receiving an active drug may be more likely to comply to treatment 
if they experience a drug effect that participants receiving placebo cannot experience. 
On the other hand, participants receiving an active drug may be less likely to comply to 
treatment if they experience adverse effects that participants receiving placebo don’t 
experience. Compliers to an active treatment in one group and compliers to placebo in 
another group may thus be incomparable, while the overall treatment groups would of 
course be comparable due to randomization.
To obtain unbiased estimates for complying participants in the intervention group of 
a trial, the effect estimates for compliers in the intervention group could be compared 
to the effects for those in the control group, who would have complied to the treatment 
had they been randomized to the intervention group (so-called ‘would-be-compliers’). 
This comparison can be made using an average causal effects (CACE) analysis (2, 3). 
Of course, the active treatment was never offered to the control group participants in 
real life; therefore we have no observed compliance data in this group. Therefore, the 
CACE analysis is essentially a missing data problem in the control group; once ‘would-be-
compliers’ in this group have been identified, a normal ITT analysis can be performed.
underlying assumptions in cace analysis (3) and their translation to the Pace 
trial
1. ignorable treatment Assignment: Treatment assignment is independent of the 
potential outcomes, conditional on the observed baseline covariates (3).
 PAce: This assumption is automatically satisfied in randomized experiments.
2. Stable unit Treatment Value assumption (SuTVa):
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 a.  The potential outcomes for each person are unaffected by the treatment 
assignment of other individuals: this means there is no interference between 
patients in different groups (3).
   PAce: Although interference between individuals in different treatment groups 
could not be ruled out in PACE, it is unlikely that this has played a significant role in 
the outcomes as all participants were blinded to the treatment they observed and 
everyone received medication through the double-dummy design; this means 
that unblinding because of dosage scheme is highly unlikely. SUTVA is therefore 
considered to be fulfilled.
 b.  there is only one version of each treatment: the treatments given to each indi-
vidual within each treatment condition do not vary across individuals (3).
   PAce: Both active and control groups had one fixed treatment protocol in PACE. 
SUTVA is therefore considered to be fulfilled.
3. Monotonicity: This assumption states there are no Defiers (i.e. participants who do 
the exact opposite of the instructions given in the trial; they take the intervention if 
they’re in the control group and they don’t take the intervention when they are in the 
active group) (3).
 PAce: Because of the blinded double-dummy design used in PACE, patients in all 
groups received the same instructions and were blinded for the intervention they 
received (this means in this case, active paracetamol group and placebo group do not 
get contradicting instructions). It seems unlikely that there were Defiers in PACE.
4. exclusion restriction: Treatment assignment does not affect the outcome if it does 
not affect the treatment actually received (no direct effect of treatment assignment 
on outcome). This means there is no effect of the treatment assignment for always 
takers or never takers; therefore Always-Taker Average Causal Effect (AACE) = 0 and 
Never-Taker Average Causal Effect (NACE) = 0 (3).
 PAce: Translation of the assumption to terms used in the PACE trial: patients who 
never take or always take paracetamol for low back pain won’t experience an ef-
fect of being randomized in the PACE trial. This assumption is may not be fulfilled 
if trial randomization (i.e. telling people to take the given medication) has an effect 
on outcome through other behavior than taking pills; for example if always-takers or 
never-takers start exercising more for their back pain because of the attention given 
to the back pain during the trial.
5. Principal ignorability: Potential outcomes are the same across compliance strata, 
conditional on covariates. In other words, principal stratum membership is inde-
pendent of the potential outcomes given the observed covariates. This assumption 
implies that we can identify principal stratum membership using only the observed 
covariates. This is what enables us to find the “likely compliers” in the control group, 
using the model of compliance behavior as a function of covariates fit among treat-
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ment group members; i.e., it implies that the outcomes of the control group members 
identified as “likely compliers” actually reflect well what the potential outcomes un-
der control would have been had the treatment group compliers been in the control 
group instead (3).
 PAce: This assumption is very likely to hold as the intervention and control are so 
similar in PACE due to the blinded double dummy design.
6. missing Values assumptions:
 a.  missing at random (mar) assumption: Non-response is associated with non-
compliance only among individuals with observed compliancy information. The 
probability of the outcome being recorded is not associated with the outcome 
conditional on treatment assignment, observed treatment receipt status and pre-
treatment covariates. Under this assumption, missingness is not attributable to 
unobserved data, including unobserved compliance status (3).
   PAce: This assumption is unlikely to hold in PACE, as nonresponse in the placebo 
group is very likely to be associated to the trial outcomes (i.e. participants who 
have recovered are less likely to continue filling out the trial questionnaires). 
However, the vast majority of patients provided data for the primary outcome in 
PACE (97%). For this reason, missing data were not considered influential in the 
CACE analyses presented in this article.
 b.  response exclusion restriction (rer) assumption: For never-takers, the prob-
ability of outcomes being recorded is not affected by treatment assignment status. 
This assumption will be violated if response probability is affected by treatment 
assignment. This means it is violated if never-takers provide outcome data more 
when assigned to the intervention condition then when assigned to the control 
condition (3).
   PAce: This assumption may hypothetically be violated in 2 ways:
  •  Poorly complying participants may have felt some benefit from active 
paracetamol and might have felt more obliged to provide outcome informa-
tion when assigned to the active regular paracetamol group than when as-
signed to the placebo group.
  •  Poorly complying participants might have been demoralized when assigned 
to the intervention condition, by failing to comply with the intervention. This 
might not have happened if they had been assigned to the placebo group.
 c.  Stable complier response (Scr) assumption: For compliers, the probability of 
outcomes being recorded is not affected by treatment assignment status. This 
assumption will be violated if response probability is affected by treatment as-
signment. This means it is violated if compliers provide outcome data more when 
assigned to the intervention condition then when assigned to the control condi-
tion (3).
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  PAce: This assumption may hypothetically be violated in 2 ways:
  •  Compliers may have felt some benefit from active paracetamol and might 
have felt more obliged to provide outcome information when assigned to the 
active regular paracetamol group than when assigned to the placebo group.
  •  Compliers might have been demoralized when assigned to the placebo 
condition because they did not feel any effect despite taking the prescribed 
medication. This might not have happened if they had been assigned to the 
intervention group.
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Supplementary results
Baseline characteristics of the complete regular paracetamol and placebo groups (as 
shown in the original analysis) are presented with corresponding standardized differences 
(St.Diffs) in Supplementary Table 1; due to chance, significant differences were found for 
employment status and household income. Because no significant differences could be 
found in all other baseline characteristics, we still assume correct randomization.
estimates of the cace models compared to Per Protocol analysis
Mean differences and corresponding p-values were very similar between Per Protocol 
analysis and joint modeling CACE for all outcomes that were assessed (Supplemental 
Table 2). A reason for this may be that in this trial, inferred compliance behavior to regu-
lar paracetamol in the placebo group was similar to observed compliance to placebo in 
this group. However, it should be noted that Per Protocol analysis should not be routinely 
used to account for non-compliance, as using this statistical technique may lead to biased 
effect estimates (3, 4).
Technical considerations about this cace analysis
Three assumptions are used in CACE analysis (3). The first assumption is ignorable 
treatment assignment, which states that treatment assignment is independent of the 
potential outcomes, conditional on the observed baseline covariates. This assumption 
is automatically satisfied in randomized experiments. The second assumption is stable 
unit treatment value assumption (SUTVA), which states two things: firstly, the potential 
outcomes for each person are unaffected by the treatment assignment of other individu-
als and secondly, there is only one version of each treatment, meaning that treatments 
given to each individual within each treatment condition do not vary across individuals. 
It is unlikely that SUTVA has been violated in PACE due to the fixed treatment protocols 
and double-dummy design, which prevents unblinding and thus interference between 
participants. The third assumption is monotonicity, which states that there are no defiers 
(participants who do the exact opposite of the instructions given in the trial. Because all 
patients received the same instructions and blinding was shown to have been successful, 
it is unlikely the monotonicity assumption has been violated in PACE (5).
In joint modeling CACE estimation, exclusion restriction is an additional underlying 
assumption; this assumption states that treatment assignment does not affect the 
outcome if it does not affect the treatment actually received (i.e., there is no direct 
effect of treatment assignment of the outcome). In propensity-weighted CACE estima-
tion, exclusion restriction is replaced by principal ignorability; this assumption states 
that principal stratum membership is independent of the potential outcomes given the 
observed covariates. In practice, exclusion restriction is unverifiable and can hardly ever 
be completely dismissed; in PACE, it could very well be that receiving instructions to 
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take medication may lead to always-takers or never-takers of medication being more 
active, which in turn could affect the outcomes of their back pain. However, in settings 
like the PACE trial where there is no effect of the intervention at all, the exclusion restric-
tion assumption is automatically satisfied and joint modeling CACE estimation is likely 
to perform very well (given no severe deviations from normality of outcome variables); 
although the assumption is not necessarily violated, principal ignorability propensity-
weighted CACE estimation does not necessarily perform well in this scenario (3). For this 
reason, we expect the joint modeling approach will have resulted in the more reliable 
CACE estimates of the two methods used.
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APPendiX 2: SuPPLeMentAry tABLeS And figureS
Supplementary table 1: Baseline characteristics for complete patient groups (ITT).
Patient characteristics All patients (ITT)
Paracetamol (N = 550) Placebo (N = 547) Standardized
difference
Age (years) 44.1 (14.8) N = 550 45.4 (15.9) N = 546 0.085
Women 263/547 (48%) 245/544 (45%) 0.061
Private health insurance 275/550 (50%) 248/544 (46%) 0.088
Currently employed 424/550 (77%) 389/542 (72%) 0.122*
Household income per week (per year) 0.179*
Negative or no income 19/540 (4%) 22/531 (4%)
AUD 1-649 (1-33799) 133/540 (25%) 168/531 (32%)
AUD 650-1699 (33800-88399) 243/540 (45%) 226/531 (43%)
AUD 1700-3999 (88400-207999) 119/540 (22%) 97/531 (18%)
≥AUD 4000 (≥208000) 26/540 (5%) 18/531 (3%)
Use of drugs for another disorder 201/550 (37%) 202/544 (37%) 0.012
Episode characteristics
Days since onset of pain 10.1 (10.1) N = 550 9.7 (9.8) N = 546 0.039
Number of previous episodes 6.3 (13.7) N = 547 7.2 (16.8) N = 544 0.058
Presence of pain extending beyond the knee 108/547 (20%) 99/544 (18%) 0.039
Number of days reduced usual activity 3.7 (6.3) N = 548 3.4 (5.3) N = 545 0.075
Disability (RMDQ) 12.8 (5.6) N = 543 13.3 (5.5) N = 531 0.081
Feelings of depression in last week 3.2 (2.9) N = 547 3.1 (2.9) N = 546 0.048
Perceived risk of persistent pain 4.5 (2.8) N = 548 4.4 (2.8) N = 545 0.050
Back pain episode compensable 31/546 (6%) 43/546 (8%) 0.088
Pain intensity 6.3 (1.9) N = 550 6.2 (1.8) N = 546 0.054
Global rating of symptom change 0.0 (2.1) N = 548 -0.1 (2.1) N = 546 0.046
Poor sleep quality 273/549 (50%) 272/546 (50%) 0.002
Function (Nominated Activity) 3.5 (1.7) N = 547 3.7 (1.9) N = 545 0.069
Quality of life – physical (SF-12) 42.7 (9.1) N = 537 42.1 (9.2) N = 538 0.065
Quality of life – mental (SF-12) 44.1 (7.7) N = 537 44.4 (7.9) N = 538 0.040
Credibility score (CEQ) 19.0 (4.9) N = 544 19.4 (4.9) N = 540 0.078
Expectation score (CEQ) 19.7 (5.3) N = 544 20.2 (5.1) N = 542 0.093
St.Diffs: Standardized Differences; Data are mean (SD) or n/N (%);* under standardized differences in-
dicate St.Diffs > 0.1. AUD: Australian Dollar; LBP: Low Back Pain; NRS: Numerical Rating Scale; RMDQ: 
Roland Morris Disability Questionnaire; SF-12; 12-item Short Form Survey; CEQ: Credibility/Expectancy 
Questionnaire.
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Supplementary table 2: Outcomes of PACE trial (Pain Intensity, Disability, Global Rating of Symptom 
Change and Function) at week 2 with compliance defined as an average intake of ≥4 tablets per day for 
regular paracetamol group vs placebo group.
Outcome Per Protocol Joint Modeling CACE
Pain Intensity (NRS)
(scale range 0-10)
0.29 (-0.074, 0.65)
p = 0.12
0.23 (-0.16, 0.62)
p = 0.24
Disability (RMDQ)
(scale range 0-24)
0.41 (-0.40, 1.22)
p = 0.32
0.37 (-0.55, 1.30)
p = 0.43
Global Rating of Symptom Change
(scale range -5 to +5)
-0.13 (-0.44, 0.18)
p = 0.41
-0.083 (-0.42, 0.25)
p = 0.62
Function (Patient Specific Function Scale)
(scale range 0-10)
-0.28 (-0.65, 0.089)
p = 0.14
-0.28 (-0.67, 0.11)
p = 0.16
All values represent mean difference (lower limit of 95% CI, upper limit of 95% CI) p value; mean dif-
ferences calculated by subtracting placebo group mean from regular paracetamol group mean. Values 
rounded to 2 significant figures. NRS: Numerical Rating Scale; RMDQ: Roland Morris Disability Question-
naire.
Supplementary table 3: Assessment for residual imbalances between the regular paracetamol group 
and weighted placebo group in the distribution of categorical variables after the weighting procedure 
in propensity-weighted CACE analysis at week 2 with compliance defined as an average intake of ≥4 
tablets per day.
Variable Placebo 
(proportion)
Paracetamol 
(proportion)
Standardized difference
Back Pain episode compensable 0.054 0.053 0.00314
Use of drugs for another disorder 0.42 0.36 0.134*
Women 0.35 0.46 0.226*
Household income per week (per year): 0.035 0.031 0.0228
Negative or no income 0.24 0.24 0.00158
AUD 1-649 (1-33799) 0.48 0.46 0.0440
AUD 650-1699 (33800-88399) 0.16 0.22 0.137*
AUD 1700-3999 (88400-207999) 0.090 0.062 0.106*
≥AUD 4000 (≥208000) 0.098 0.17 0.223*
Private health insurance 0.54 0.51 0.0618
Poor sleep quality 0.55 0.50 0.0962
Currently employed 0.74 0.78 0.0838
St.Diffs: Standardized Differences; * under standardized differences indicate St.Diffs > 0.1; AUD: Austra-
lian Dollar.
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Supplementary table 4: Assessment for residual imbalances between the regular paracetamol group 
and weighted placebo group in the means of continuous variables after the weighting procedure in 
propensity-weighted CACE analysis at week 2 with compliance defined as an average intake of ≥4 tab-
lets per day.
Variable Placebo mean (SD) Paracetamol mean (SD) Standardized 
difference
Quality of life – mental (SF-12) 45.46 (15.19) 44.08 (6.72) 0.0908
Quality of life – physical (SF-12) 40.91 (17.26) 42.34 (7.82) 0.0831
Age 49.33 (31.27) 44.77 (12.86) 0.146*
Days since onset of pain 10.28 (19.31) 10.12 (8.63) 0.00862
Number of days reduced usual activity 4.57 (12.95) 3.83 (5.53) 0.0571
Credibility score (CEQ) 20.04 (9.02) 19.13 (4.19) 0.100*
Perceived risk of persistent pain 5.14 (5.32) 4.77 (2.35) 0.0700
Feelings of depression in last week 3.57 (6.04) 3.34 (2.49) 0.0381
Expectation score (CEQ) 20.81 (9.00) 19.94 (4.64) 0.0967
Function (Nominated Activity) 3.40 (3.63) 3.43 (1.41) 0.00664
Global rating of symptom change -0.12 (4.11) -0.01 (1.81) 0.0262
Pain intensity 6.20 (3.53) 6.29 (1.59) 0.0251
Number of previous episodes 6.39 (27.04) 6.31 (11.33) 0.00326
Disability (RMDQ) 13.11 (10.65) 12.87 (4.67) 0.0233
St.Diffs: Standardized Differences; * under standardized differences indicate St.Diffs > 0.1; RMDQ: Roland 
Morris Disability Questionnaire; SF-12; 12-item Short Form Survey; CEQ: Credibility/Expectancy Ques-
tionnaire.
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Supplementary figure 1: Graphical assessment for residual imbalances between the regular 
paracetamol group and weighted placebo group in the distribution of categorical variables after the 
weighting procedure in propensity-weighted CACE analysis at week 2 with compliance defined as an 
average intake of ≥4 tablets per day.
121
cAce analysis of the PAce trial
6
Quality of life – 
mental (SF) 
Quality of life – 
physical (SF) 
Age 
Days since onset of 
pain 
Number of days 
reduced usual activity 
Credibility score 
(CEQ) 
Perceived risk of 
persistent pain 
Feelings of depression 
in last week 
Expectation score 
(CEQ) 
Function (Nominated 
Activity) 
Global rating of 
symptom change 
Pain intensity 
Number of previous 
episodes 
Disability (RMDQ) 
Supplementary figure 2: Graphical assessment for residual imbalances between the regular 
paracetamol group and weighted placebo group in the means of continuous variables after the weight-
ing procedure in propensity-weighted CACE analysis at week 2 with compliance defined as an average 
intake of ≥4 tablets per day.
0: Paracetamol; 1: Placebo.
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ABStrAct
Introduction
In people with acute low back pain (LBP), there may be an association between reporting 
adverse events (AEs) of treatment and outcomes of LBP. This study aimed to 1) investi-
gate the association between baseline characteristics of participants and reporting AEs 
and 2) the association between reporting treatment related AEs and outcome in people 
with acute LBP.
Methods
Data from the PACE-trial, evaluating paracetamol versus placebo in acute LBP, was used in 
this analysis as an observational cohort. The association between baseline characteristics 
and reporting AEs by participants was investigated using a logistic regression model. The 
association between reporting AEs and outcomes of LBP was investigated using mixed 
effects models for LBP intensity, physical functioning and health-related quality of life 
(hrQoL) and Cox proportional hazards models for time until recovery.
results
Reporting any AE was strongly associated with the use of medicines for a health prob-
lem other than LBP (odds ratio (95% CI) 1.42 (1.07-1.88)). Reporting any AE was not 
associated with less favorable outcomes for LBP intensity, physical functioning, hrQoL 
or time until recovery (respective coefficients 0.00 (-0.07-0.07), 0.02 (-0.05-0.10), -0.44 
(-1.08-0.20), -0.54 (-1.37-0.29) and HR 1.09 (0.94-1.26)). Due to the very low number of 
serious AES (death or hospitalization) there was insufficient information to investigate 
the association between reporting these AEs and baseline characteristics or the associa-
tion with outcomes of LBP.
conclusions
In the PACE trial, reporting adverse events after using paracetamol or placebo was as-
sociated with the use of medicines for other health problems, but not with (unfavorable) 
outcomes of LBP.
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The aim of this thesis was to elucidate the current role of paracetamol in the treatment 
of low back pain (LBP) in primary care. In order to do so, we first compared the recom-
mendations on the pharmacological management of LBP in national clinical practice 
guidelines. Subsequently, we intended to reproduce the results of the Paracetamol 
for Acute Low Back Pain (PACE) trial (1) in a follow-up clinical trial (i.e. the PACE-plus 
trial), but had to discontinue this trial due to insufficient patient recruitment. Finally, we 
conducted three secondary analyses using data collected in the PACE trial: we tested 
the inferential reproducibility of the conclusions drawn in PACE, we investigated the 
efficacy of paracetamol in acute LBP among participants who complied with regular 
paracetamol treatment, and we explored the association between reporting adverse 
events of paracetamol and outcomes of LBP. In the current chapter, we place the most 
important findings from these research projects in the context of prior knowledge and 
discuss the methodological limitations of this thesis. We end this chapter by discussing 
the implications of these findings for clinical practice and future research.
8.1 interPretAtion of the PrinciPAL findingS in the conteXt of Prior 
knowLedge
8.1.1 Variation in guideline recommendations for the pharmacological 
management of low back pain
In chapter 2, we presented the results of our systematic literature review of recom-
mendations on the pharmacological management of LBP. The most striking result of 
this review was the difference between the analgesics of first choice of the eight recent 
national clinical practice guidelines. Four out of eight guidelines (Australia, Canada, Den-
mark and the Netherlands (2-5)) still recommend the prescription of paracetamol for LBP, 
while the other four guidelines (Belgium, Germany, Britain and the US (6-9)) recommend 
non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice analgesic; furthermore, 
the American guideline offers a choice between NSAIDs and skeletal muscle relaxants.
There may be a number of explanations why the results from the PACE trial (1) have 
not been taken up by four recent guidelines. First of all, policymakers behind the guide-
lines may have considered the results of a single randomized-controlled trial (RCT) as 
insufficient evidence to change their recommendations. Second, the lack of a safe and 
effective alternative could have played a role; in fact, NSAIDs, i.e. the next step on the 
WHO pain ladder (10), are contra-indicated in many primary care patients (for instance 
due to gastro-intestinal or cardiovascular comorbidity (11)). More importantly, both the 
review by Machado and colleagues (12) and the upcoming revision of the Cochrane 
systematic review regarding the efficacy of NSAIDs for acute LBP (Van der Gaag et al, 
submitted work) question whether the difference between NSAIDs and placebo is clini-
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cally relevant. For pain intensity, Machado and colleagues found a mean difference of 9.2 
on a 100-point scale in favor of NSAIDs up to 2 weeks of follow-up, which is very similar 
to Van der Gaag and colleagues’ mean difference of 7.3 up to 3 weeks of follow-up. For 
physical function, the two meta-analyses used different scales: Machado and colleagues 
found a mean difference of 8.1 points on a 100-point scale in favor of NSAIDs up to 2 
weeks of follow-up, where Van der Gaag and colleagues found a mean difference of 2.02 
point on the 24-point Roland-Morris Disability Questionnaire (RMDQ) up to 3 weeks of 
follow-up. These mean differences correspond to a 20% extra improvement in people 
receiving NSAIDs as compared to people receiving placebo; this generally considered to 
be the smallest worthwhile effect (13, 14). Furthermore, in head-to-head comparisons 
of NSAIDs and paracetamol, it was found that these medicines are equally effective for 
pain intensity and physical functioning in patients with acute LBP, while NSAIDs were as-
sociated with more adverse effects as compared to paracetamol (15-19). Third, the four 
mentioned guidelines may not have implemented the PACE results because of the safety 
profile of paracetamol, which is still perceived as relatively safe (20). However, results 
from observational research have shown that this may not be justified (21); paracetamol 
overdose is the number one cause of acute liver failure worldwide (22), and patients 
taking paracetamol have an increased risk of gastro-intestinal, cardiovascular and renal 
AEs (21). Finally, the results of PACE have been challenged as due to non-compliance 
to treatment (23, 24); uncertainty regarding the efficacy of paracetamol in compliers 
may have been a reason for policymakers not to change the existing recommendations 
regarding this drug. This uncertainty is addressed in detail in chapter 6.
At first glance, it seems counterintuitive that only the American and Canadian guideline 
recommend skeletal muscle relaxants for acute LBP as these drugs could provide a clini-
cally relevant effect on pain on the short term (9). Abdel Shaheed’s meta-analysis found 
a mean difference of 21.3 points on a 100-point scale in favor of skeletal muscle relaxants 
at 3 months follow-up (25). The main reason why the other guidelines did not make any 
recommendations about skeletal muscle relaxants may be because they are not widely 
available outside North America. This begs the question of whether we are missing out 
on these drugs in Europe or not. Surprisingly, the correct answer to this question may be 
that we are not. Although the effect on pain was considered to be clinically relevant, the 
effect on disability was not: the mean difference was 6.5 points on a 100-point scale in 
favor of skeletal muscle relaxants (25). Furthermore, a recent RCT, which could not yet be 
included in Abdel Shaheed’s meta-analysis, that compared a combination of ibuprofen 
and skeletal muscle relaxants (baclofen, metaxalone or tizanidine) to a combination of 
ibuprofen and placebo concluded that adding skeletal muscle relaxants to ibuprofen did 
not improve pain or physical functioning after one week of follow-up in patients that 
visited the emergency department for acute LBP (26). Moreover, skeletal muscle relax-
ants are associated with unpleasant adverse events (sedation, nausea, vomiting, vision 
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problems, headaches and dizziness), a potential for abuse and dependency and sub-
stantial costs (27). As there is still uncertainty about the balance between benefits and 
harms of skeletal muscle relaxants, more research is needed before adequate guideline 
recommendations can be made about the use of these drugs for the treatment of acute 
LBP.
The most important conclusion from the systematic review presented in chapter 2 is 
that although guidelines are universally moving away from recommending pharmaco-
therapy, there is currently no consensus regarding the analgesic of first choice in case 
patients do require medication. From the meta-analyses that we considered as best 
available evidence for the efficacy on drug efficacy, it can be concluded that all pharma-
cological treatments only have small to moderate short-term effects for non-specific LBP 
at best. Considering that for the majority of patients, the natural course of acute LBP is 
favorable (28), the best treatment of non-specific LBP in primary care may therefore not 
be the one with the best efficacy, but the one with the least side effects. Following this 
principle, the American guideline recommends nonpharmacological treatments (the ef-
ficacy of which is also small to moderate at best) rather than pharmacological treatment 
for recent-onset non-specific LBP (9). It is now up to policymakers from other countries 
whether they choose to follow this example in the upcoming revisions or not.
Limitations
The most important limitation of chapter 2 is that it was a narrative review, in which a 
number of arbitrary decisions were made in the methods. An example is the criterion 
to include only ‘recent’ clinical practice guidelines, which we defined as published after 
January 1st, 2016. However, as it was our aim to compare recent guidelines to the best 
available evidence, a limit would have been necessary in any case, and the definition of 
recentness would always have been subjective. Another design choice that could have 
influenced the results was restriction of languages to English, German or Dutch. Because 
of these criteria, we could have missed clinical practice guidelines. However, when we 
compare the guidelines included in our review to another recent overview aiming to 
investigate the consensus among clinical practice guidelines, we can see we did not miss 
any guideline because of language restrictions (29). Finally, it is difficult to judge what 
the ‘best available evidence’ is. As new studies are constantly published, we decided 
the best available evidence regarding the efficacy of pharmacological treatments would 
be in the most recent systematic reviews and meta-analyses, which constitute the top 
of the evidence pyramid (30). Alternatively, we could also have chosen to include only 
adequately powered RCTs with low risk of bias (31). Irrespective of these limitations, this 
review provided a valuable overview to provide context for other projects in this thesis.
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8.1.2 The development and discontinuation of the Pace Plus trial
A protocol for a clinical trial to follow-up the Australian PACE trial (1) was presented 
in chapter 3. With the PACE Plus trial, we attempted to reproduce the results of PACE 
by comparing paracetamol and placebo for the treatment of acute non-specific LBP in 
primary care; simultaneously, we also intended to compare paracetamol to diclofenac, 
the most prescribed NSAID in the Netherlands (32), and one of the most used NSAIDs 
worldwide (33). Finally, we planned to compare the combination of advice and medi-
cation (paracetamol or diclofenac) to advice alone. Together, these comparisons were 
designed to answer three important research questions that arose after publication of 
the results of the PACE trial. First, can the results of the PACE trial be reproduced? Sec-
ond, considering that NSAIDs have not been demonstrated to be consistently superior 
to paracetamol (15-19), which in turn has been shown not to have a clinically relevant 
effect on LBP as compared to placebo (1), what is the comparative effectiveness of 
paracetamol, diclofenac and placebo for acute LBP? Third, would treating patients with 
acute LBP with advice and reassurance only be inferior to treating these patients with 
paracetamol or diclofenac?
After 6 months of recruitment in the PACE Plus trial, only four of the required 800 
patients with LBP had been recruited, leading to the discontinuation of the RCT. In order 
to investigate the underlying reasons for termination of this RCT, we conducted a survey 
among local research coordinators of the participating GP practices; results of this sur-
vey have been shown in chapter 4. GPs mentioned an insufficient number of patients 
meeting the study’s eligibility criteria, lack of time in daily practice, and different patient 
expectations as the three main reasons for failed patient recruitment in PACE Plus (in 
order of descending number of comments); together, these three reasons formed over 
half of all reasons reported in the survey (48 out of 81 reported reasons). In a systematic 
literature review investigating factors that limit the progress of RCTs, common barriers to 
participation in clinical trials were very similar to what was found in the survey in chapter 
4 (34).
The reduced number of patients with acute LBP seeking help in general practice when 
compared to the reported incidence of acute LBP in the Netherlands (35) could be ex-
plained by Lasagna’s law (36, 37), the observation that once a trial starts, the number of 
available patients is between a tenth and a third of what was originally expected by the 
researchers (37). This was first described by American physician Louis Lasagna, who de-
fined this phenomenon as “the incidence of patient availability sharply decreases when 
a clinical trial begins” (38). Explanations for Lasagna’s law may be that researchers and 
clinicians overestimate the number of available patients before the study (for instance 
because not all patients with a new episode of disease are willing to be randomized), or 
that clinicians have insufficient time to recruit available cases. Another reason for this 
suspected drop in incidence could be due to a true decline in GP visits between the mea-
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surement of the incidence of LBP (which was in 2012) and the start of the PACE Plus trial 
(which was in September of 2016). An explanation of such a development could be the 
launch of the patient information website of the Dutch College of General Practitioners, 
which happened in March 2012 (39, 40). In 2014, this website already had 2.9 million 
unique views per month, and a decline of 12% in consultations in general practice was 
attributed to the website launch; it is highly likely that this reduction in consultations has 
become even larger in the five years that have passed since then, as the number of unique 
views per month has increased to 4.6 million in June 2019 (39, 41). The recommenda-
tions on the web page about LBP are mainly aimed at improving self-management of 
complaints: they focus on the favorable prognosis of LBP, the limited benefits of medica-
tion and imaging and the necessity to remain active. This information could have directly 
contributed to one of the other reasons for insufficient patient recruitment mentioned 
in the survey, namely the effective self-management of LBP. Another explanation of a 
true decline in GP visits of patients with LBP could be the increasing popularity of direct 
access to physiotherapy; in 2017, 56% of patients used direct access to physiotherapy as 
compared to 35% in 2009 (42, 43). Apart from the change in number of patients visiting 
their GP with recent onset LBP, there may also have been a change in type of patients 
with LBP presenting in general practice. Patients who recovered using self-management 
skills only might not visit their GP, whereas the patients seeking care with their GP may 
have had LBP for a longer period, with greater limitations of their usual daily activities 
and with unsatisfactory results using over-the-counter medication such as paracetamol 
and NSAIDs. If this is the case, it seems logical that these patients have different expecta-
tions than participating in a trial that offers them exactly the same interventions they 
have been using for a number of weeks. In light of this suspected changing population of 
patients presenting to general practice with recent onset LBP, recruiting incident cases of 
LBP from Dutch general practice for research into first-choice interventions may remain 
a challenge. However, conducting research in clinical practice is not just a challenge in 
the Netherlands, but also in other countries such as the United States and the United 
Kingdom (44); the feasibility of such a study is thus not automatically guaranteed if it 
were to be conducted in another country.
The second most frequent reason (i.e. lack of time in general practice) seems to reflect 
the current state of general practice in the Netherlands. Because of changes in the na-
tional health care system, the range of tasks of the Dutch GP has vastly increased, as has 
the related administrative workload; similar increases in workload have been reported 
in England, which has a similar organization structure of primary care (45). In 2015, this 
even led to an action group presenting a manifesto to the House of Representatives of 
the Netherlands signed by two-thirds of all Dutch GPs (a total of 7800 signatures), in 
which they asked for health care system reforms (46). In an international comparison of 
the workload of general practitioners, it was found that Dutch GPs spent a large percent-
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age of time on tasks that were not directly patient-related, such as administration, when 
compared to GPs from other countries (47). Although some positive changes have been 
made in recent years, such as the decrease in number of patients per practice, conduct-
ing clinical trials in Dutch general practice (for any clinical condition) will probably remain 
difficult in the foreseeable future.
GPs could be encouraged to participate in research by allowing for adequate reim-
bursement of their invested time. Even though a Dutch study investigating the factors 
related to success and failure of patient recruitment did not identify GP reimbursement 
as a factor influencing trial success (36), the comparison between PACE Plus and the 
original PACE trial revealed this may have been an important difference between the 
Australian and the Dutch trial. However, this would require an increase in the budget of 
research projects, which would probably only be possible in collaborations with the phar-
maceutical industry. Contrary to the reasoning in the Cochrane Risk of Bias assessment 
tool (31), industry involvement does not always have to be a cause for concern, as long 
as corporate sponsors are not involved in study design and analysis and interpretation 
of results, as demonstrated by the PACE trial (1); however, it will very likely be difficult 
to obtain industry funding under these terms in practice. As an alternative solution, the 
Australian system for mandatory continuing education, in which part of the points obliga-
tory for re-registration as a GP can only be earned by participating in research, could be 
implemented in the Netherlands.
Limitations
The most significant limitation of the PACE Plus trial was by far its feasibility. With dif-
ferent study design choices, the trial may have been more likely to succeed. A number 
of general recommendations for future research have already been made in chapter 
3. As the specific research questions of PACE Plus remain relevant but unanswered, an 
alternative approach to PACE Plus is presented in Section 8.3.
From a technical perspective, a limitation of the PACE Plus trial was the fact that it is 
not strictly speaking a results reproduction study according to Goodman’s new lexicon of 
research reproducibility (48). Goodman describes results reproduction as the collection 
of new data in the same population and consequently analyzing this data using the same 
analysis plan (48). Although the first criterion was met (both trials were set in primary 
care, albeit on opposite sides of the globe), the second was not. While the original PACE 
trial had three treatment groups (paracetamol taken regularly, paracetamol as-needed 
for pain and placebo), PACE Plus had four (paracetamol, diclofenac, placebo and advice 
only), meaning a different analysis plan was needed. Furthermore, not all outcomes were 
identical between the two trials, the most notable difference being the measurement of 
health-related quality of life (HRQoL), which we intended to record using the EuroQol 
Group 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L (49)) rather than the Short Form 
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12 (SF-12 (50)) that was used in the original trial. These instruments provide different 
HRQoL scores (i.e. the EQ-5D-5L provides overall utility and visual analogue scale scores, 
whereas the SF-12 provides a physical and a mental summary score) that make a com-
parison very difficult to do (Chiarotto 2018 Pain). But although PACE Plus was not strictly 
speaking a results reproduction study, data on pain intensity, disability and time until 
recovery from LBP from PACE Plus could have been combined with data of PACE in an 
individual patient data (IPD) meta-analysis (51), had the PACE Plus trial been completed.
An important technical consideration about the survey in chapter 3 was the way the 
survey was conducted. Although the response rate among local research coordinators 
was high (92%), it is debatable whether these 33 research coordinators were repre-
sentative of all 96 GPs that participated in the trial. Furthermore, the survey was not a 
structured combination of open- and close-ended questions, as it solely consisted of a 
single open question. By performing a more elaborate survey among all participating GPs 
rather than only the local coordinators, a more valid picture could have been obtained; 
however, given the high workload of GPs, a more elaborate survey would likely have 
had a much lower response rate and thus a poorer representation of the participating 
clinicians.
8.1.3 Secondary analyses of data collected in the PAce trial
Three projects presented in this thesis were based on secondary statistical analyses of 
data collected in the PACE trial (1). Our first re-analysis of PACE focused on the reproduc-
ibility of the knowledge claims made in the original data analysis. One of the reasons for 
failed patient recruitment in PACE Plus mentioned by four GPs in the survey in chapter 4 
was that the research question of the PACE Plus trial was irrelevant for clinical practice, 
since the original PACE trial had already sufficiently investigated efficacy of paracetamol 
for LBP. However, reproducibility is one of the cornerstones of scientific research (52) 
and many scientific claims are found not to be reproducible (53-55). In chapter 5, we 
presented the results of the first independent inferential reproducibility study in the LBP 
research field. This study focused on the reproduction of the causal inferences of the 
PACE trial for the core outcome domains of LBP: pain intensity, physical functioning and 
HRQoL (56). We analyzed the data in the PACE trial with an independent team using the 
pre-defined and published statistical analysis plan from the PACE Plus trial; the original 
PACE trial authors had no influence on the aim, methods and conclusions of this study 
and effectively gave us “carte blanche” to conduct this analysis. In the reproducibility 
study, paracetamol had no effect on the core outcomes when compared to placebo.
In our second analysis, we investigated the efficacy of paracetamol among partici-
pants who complied to treatment. As stated earlier, although it was demonstrated that 
paracetamol had no overall effect on outcomes of acute LBP when compared to placebo 
(1), it was unclear if there was a difference between paracetamol and placebo in compli-
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ers to the treatment regimen; this may have played a role in the observation that four 
recent guidelines did not change their recommendation regarding paracetamol for LBP. 
In chapter 6, we showed that paracetamol was not more effective than placebo for acute 
LBP, regardless of the definition of compliance or follow-up period, using a complier aver-
age causal effects (CACE) analysis.
In chapter 7, we presented our secondary analysis of PACE, in which we looked 
into the association of reporting adverse events (AEs) and on the one hand, baseline 
characteristics and on the other hand, outcomes of LBP. Baseline characteristics that 
were associated with reporting AEs were older age, more days since the onset of pain, 
increased feelings of depression. The strongest association was found for the use of 
medicines for a health problem other than LBP (odds ratio 1.42, 95% confidence interval 
1.07 – 1.88), suggesting that not all reported AEs were related to taking trial medication. 
No association was found between reporting AEs and the core outcome domains of LBP 
at follow-up (56).
These findings should be interpreted in the context of the original (primary) analysis of 
the PACE trial (1). The fact that the results from the independent inferential reproduction 
analysis are consistent with the original results of PACE, even though a different approach 
to the statistical analysis was used, strengthens the conclusions regarding the lack of 
efficacy of paracetamol for acute LBP. Our second analysis represented only the second 
time the CACE analysis technique was used in the LBP research field (57). The findings of 
this study extend the message of the original analysis of PACE and form a strong appeal 
to clinicians and policymakers to reconsider their endorsement of paracetamol for the 
treatment of acute LBP. Finally, our findings in the AEs analysis suggested that if LBP-
patients decide to take paracetamol anyway and consequently experience AEs, overall 
this is not associated with less favorable outcomes of LBP. If we combine all these results, 
the bottom line seems to be that taking paracetamol has very little influence (neither 
negative nor positive) on the outcomes of acute LBP.
Limitations
The most important limitation of the studies presented in chapters 5, 6 and 7 was that 
existing data regarding the efficacy of paracetamol for acute LBP was used; no new data 
was collected during these studies. An additional disadvantage of this is that the available 
data was not intended to conduct a CACE analysis on or to investigate the association 
between reporting AEs of paracetamol and outcomes of LBP. The accuracy of the CACE 
analysis could have been improved by including a measurement for the likelihood of 
compliance in the baseline questionnaire (58). An important limitation of the AEs analy-
sis is there was no verification whether or not reported AEs were related to taking study 
medicines in PACE.
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8.2 iMPLicAtionS for cLinicAL PrActice
In spite of the fact that the evidence for a lack of efficacy of paracetamol for acute LBP 
has been strengthened by the studies in this thesis, the most important piece of the 
puzzle is still missing: results reproduction of the PACE trial. However, irrespective of the 
efficacy of paracetamol, it seems that GPs may have taken a wrong turn somewhere in 
the past decades when it comes to the management of LBP, considering the evidence 
presented in chapter 2. We still tend to focus on pain intensity and the treatment of 
pain until a pain level of zero is reached, rather than focusing on the influence that LBP 
has on the daily activities of our patients and the treatment until an acceptable level of 
functioning is achieved (56, 59-61).
Although the treatment of pain in evidence-based medicine is currently strongly asso-
ciated with the prescription of medication, we must not forget that there are other thera-
peutic options in clinicians’ toolkits. Treatment options for acute LBP that are feasible, 
affordable and available today include superficial heat, massage, or exercise, irrespective 
of their specific efficacy; research investigating placebo-interventions suggests that for 
patient reported outcomes, almost any intervention is better than no intervention at all 
(62). Furthermore, even open-label placebo interventions have demonstrated clinically 
relevant effects on pain, given that they are provided in a positive context (63). Ideally, 
these suggested non-pharmacological treatments should therefore be wrapped in the 
best possible ‘therapeutic envelope’, which is also known as the patient-provider interac-
tion. In a time when it has been shown that most pharmacological treatments have no 
clinically relevant effects, larger benefits may be expected from maximizing contextual 
effects than from the development of new drugs.
Instead of a clear and unambiguous recommendation for clinical practice, this thesis 
provides an ethical dilemma: should clinicians still prescribe paracetamol to patients 
with acute LBP, now that we know that even in patients who comply with the treatment 
regimen, it has no effect when compared to placebo? On the one hand, one could argue 
they should; placebos are associated with effects on patient reported outcomes (64) 
and one could argue that although paracetamol is definitely not harmless (21), of all the 
analgesics, it arguably has the most favorable safety profile. If clinicians stop prescribing 
paracetamol, many patients that require pain medication will be prescribed NSAIDs or 
even opioids instead. In such a scenario, are we not better off if we just continue to 
prescribe paracetamol? On the other hand, in conventional medicine, it is not acceptable 
to prescribe placebo tablets (which have no characteristic effect, but no adverse effects 
either). If paracetamol is prescribed solely for the purpose of prescribing a placebo, 
then are we not breaking our own rules? Furthermore, if we know that the effects of 
an intervention is based on the placebo effect, but we continue to use the intervention 
anyway, then what is the difference between conventional evidence-based medicine and 
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what we call alternative medicine (65)? And if we purposely prescribe paracetamol as a 
placebo, how sure are we that this placebo effect is clinically worthwhile to LBP patients 
(13, 14)?
8.3 iMPLicAtionS for future reSeArch
The discontinuation of the PACE Plus trial left a legacy of unanswered research questions. 
First, the results of the PACE trial should be reproduced. Second, the relative efficacy of 
paracetamol as compared to that of NSAIDs and other medicaments and non-pharma-
cological interventions remains unclear. Third, we still have limited and contradictory 
evidence regarding the magnitude and clinical relevance of the placebo effect in LBP 
when compared to no treatment (or waiting list controls).
Reproduction of the results of PACE will be challenging in practice, as it requires the 
collection of new data. Currently, the recruitment of incident cases of acute LBP in Dutch 
general practice does not seem realistic, given the amount of pressure GPs are already 
under due to their normal workload. However, we know that the one-year risk of recur-
rence of acute LBP is 33% (66, 67). An RCT nested in a cohort of prevalent cases of LBP 
may therefore be much more feasible. Instead of burdening GPs with patient recruit-
ment, cohort participants could be recruited through large population databases, such 
has the Integrated Primary Care Information (IPCI) database (68), a large database with 
1.5 million primary care patient records from the South of the Netherlands. For instance, 
patients for whom an ICPC-code L03 (non-radiating LBP) was registered in the past year 
could be approached via post to participate in the cohort, and could subsequently be 
instructed to contact the research department as soon as they experience a new episode 
of LBP. The most feasible approach would be to then randomize these participants to 
regular paracetamol or placebo, thus answering our research question. Another option 
would be to use a large observational dataset to answer this research question, given 
that confounding can be adequately assessed and corrected for (which is the main disad-
vantage of non-randomized studies). In this scenario, the PACE Plus design could be used 
as a target trial protocol (69).
Although our experience with PACE Plus suggests the likelihood of failure may increase 
by attempting to answer multiple research questions in one study (in RCTs, do not try to 
kill two birds with one stone), it would theoretically be possible in a cohort-nested RCT 
design to simultaneously investigate the second unanswered research question of PACE 
Plus as well. In this scenario, patients could be randomized to receive non-pharmacolog-
ical treatment only (which could consist of advice and reassurance only, superficial heat 
and or/exercises), or to receive a combination of non-pharmacological treatment and 
medication. In the latter group, patients could be allocated to different treatment options 
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(such as paracetamol, ibuprofen or placebo) using a second randomization procedure. 
A downside of this approach is that it is very costly and labor-intensive. An alternative 
approach to comparing paracetamol to other pharmacological and non-pharmacological 
interventions would be by conducting a network meta-analysis (70, 71), in which direct 
and indirect evidence is combined to reconstruct a comparison between interventions 
that have never been tested head-to-head in an RCT. Protocols have already been de-
veloped for the conduct of such network meta-analyses in order to compare the effects 
and safety of paracetamol, NSAIDs and opioids for chronic LBP (72) and to compare the 
effects of all noninvasive treatments of LBP (73).
Apart from ambiguous evidence regarding the comparative efficacy of paracetamol 
and NSAIDs, it is unclear how acceptable these treatments currently are to patients with 
LBP. NSAIDs in particular have been in the media in a negative context during recent years 
(74-76). Observational studies have been conducted for physiotherapy and NSAIDs to 
investigate when the effects of these interventions become worthwhile to LBP patients 
(13, 14). Given the fact that over the last decade, many new studies been published about 
both the efficacy and the safety of paracetamol and NSAIDs (12, 21, 77), it is important 
to update the current knowledge on when these medicines are clinically worthwhile to 
patients with LBP in order to place their efficacy into context.
The PACE Plus trial would have been the first RCT in the LBP research field to directly 
compare a combination of advice and blinded placebo tablets to advice only. The only 
similar published result would be a comparison between open-label placebo and treat-
ment as usual in people with chronic LBP (63). In this study, open label placebo pills were 
found to have a significant and possibly clinically relevant effect on both pain and dis-
ability after 3 weeks of follow-up when compared to treatment as usual (63). However, 
as this study used open-label placebo pills which were provided in a positive context, it 
is unclear whether the magnitude of the effects found in this study reflects the placebo 
effect (in this case: the effect of a placebo intervention (78)) associated with medication 
given to people with LBP. The reason why knowledge about the effect size associated 
with a placebo intervention is so important, is because active interventions are com-
pared to these placebo-interventions in clinical trials in order to determine the efficacy 
of these interventions. If the effect of placebo interventions compared to no treatment 
(or for instance a waiting list) is not clinically relevant, then this has implications for the 
interpretation of the results of placebo-controlled trials as well. Currently, the existence 
and clinical relevance of the effects of placebo interventions is a topic of debate in the 
LBP research field: on the one hand, it was found in a meta-analysis that the pooled mag-
nitude of placebo effects for pain is very small (3.2 points on a 100-point pain scale) (79) 
and on the other hand, it was concluded from a systematic review that placebo tablets 
could have a clinically meaningful effect on pain in people with non-specific LBP (80). 
However, the search strategies for these studies are now over ten years old, so many new 
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RCTs comparing placebo interventions to no treatment may have been conducted in the 
meantime (81). As stated in Section 8.2, another important topic in placebo research 
is the optimization of the patient-provider interaction (82). New research in this area 
should mainly focus on the development and implementation of specific evidence-based 
strategies for general practice. By using the doctor as a medicine, we may be able to 
avoid the pills (83).
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The aim of this thesis was 1) to describe the similarities and differences between recom-
mendations for pharmacotherapy of low back pain (LBP) from recent clinical practice 
guidelines; 2) to investigate if the results and inferences from the Paracetamol for Acute 
Low Back Pain (PACE) trial could be reproduced; 3) to assess the efficacy of paracetamol 
for acute non-specific LBP in participants of the PACE trial who complied with the treat-
ment regimen; and 4) to investigate if there is an association between reporting adverse 
events (AEs) and the outcomes of acute LBP.
In chapter 2, a systematic literature review of recommendations for non-invasive phar-
macological management of LBP from recent clinical practice guidelines was presented. 
These guidelines were compared with each other and with the best available evidence 
on drug efficacy. Eight recent national clinical practice guidelines were included in this 
review (from Australia, Belgium, Canada, Denmark, The Netherlands, UK and US). Guide-
lines are universally moving away from pharmacotherapy due to the limited efficacy and 
the risk of AEs. NSAIDs have replaced paracetamol as the first choice analgesics for LBP in 
half of the recent guidelines. Opioids are considered to be a last resort in all guidelines, 
but prescriptions of these medications have been increasing over recent years. Only 
limited evidence exists for the efficacy of antidepressants and anticonvulsants in chronic 
LBP. Muscle relaxants are one of the analgesics of first choice in the US, but they are not 
widely available and thus not widely recommended in most other countries. As phar-
macological treatments for LBP only have small to moderate effects at best, while being 
associated with a risk of AEs, upcoming guideline updates should shift their focus from 
pain to function and from pharmacotherapy to non-pharmacologic treatment options.
The PACE trial, published by Williams and colleagues in 2014, was the first large 
randomized controlled trial (RCT) to investigate the efficacy of paracetamol for acute 
LBP. A study protocol for a new RCT to follow-up on the PACE trial was presented in 
chapter 3; this new study was called the PACE Plus trial. This trial aimed to assess the 
effectiveness of paracetamol, diclofenac and placebo for patients with acute LBP over a 
period of 4 weeks and to assess the additional effectiveness of paracetamol, diclofenac 
and placebo to advice only over a period of 4 weeks. Patients with acute LBP aged 18-60 
years presenting in general practice were included and subsequently randomized into 
four groups: 1) Advice only (usual care conforming with the clinical guideline of the Dutch 
College of General Practitioners); 2) Advice and paracetamol; 3) Advice and diclofenac; 
4) Advice and placebo. The primary outcome was LBP intensity measured with a 0-10 
numerical rating scale. Secondary outcomes included compliance to treatment, physical 
functioning, perceived recovery, costs, adverse reactions, satisfaction, sleep quality, co-
interventions and adequacy of blinding.
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Due to insufficient patient recruitment, the PACE Plus trial was prematurely terminated 
within 6 months after the start of the trial. In chapter 4, the reasons behind the discon-
tinuation of PACE Plus were explored. General Practitioners (GPs) from 36 participating 
practices received a single-question survey in which they were asked to give the three 
most important factors that, in their opinion, contributed to failure of patient recruit-
ment. GPs from 33 of the 36 (92%) participating practices sent a response; a total of 
81 factors were reported. These factors were categorized into patient factors (26 out of 
81 comments, 32%), GP factors (39 out of 81 comments, 48%) and research factors (16 
out of 81 comments, 20%). Patient recruitment in the PACE Plus trial may have failed 
due to inefficient medication distribution, recruitment of incident rather than prevalent 
cases, a design that was too complicated, adequate self-management of LBP, patient 
expectations being different from the trial’s scope, and lack of time of participating GPs. 
Substantial differences in design may explain why the preceding PACE trial did manage to 
successfully complete patient recruitment. Although the PACE Plus trial was terminated 
as a result of insufficient patient inclusion, the research questions addressed in this trial 
remain relevant but unanswered.
Three secondary analyses of data collected in the PACE trial were conducted. The 
inferential reproducibility of the original conclusions of PACE was investigated in chapter 
5. An independent research team used the published analysis plan of the PACE Plus trial 
to re-analyze the PACE trial. The reproduction analyses indicated no effect of treatment 
on pain intensity and confidence intervals excluded clinically worthwhile effects (coef-
ficient for regular paracetamol versus placebo 0.00 (-0.02 - 0.01, p = 0.85); coefficient 
for paracetamol as-needed versus placebo 0.00 (-0.02 – 0.01, p = 0.92)). Similar results 
were obtained for all secondary outcomes (physical functioning, health-related quality 
of life (HRQoL), sleep quality and time until recovery). This indicated that the conclusions 
of the PACE trial were inferentially reproducible, even when using a different analytical 
approach. This reinforced the notion that management of patients with acute LBP should 
focus on providing advice and reassurance without the addition of paracetamol.
Another secondary analysis was presented in chapter 6. This study aimed to investigate 
the efficacy of paracetamol in acute LBP among compliers. Using individual participant 
data from the PACE trial, Complier Average Causal Effects (CACE), Intention-to-treat (ITT) 
and Per Protocol (PP) estimates were calculated for pain intensity (primary), physical 
functioning, global rating of symptom change and executive functioning (all secondary) 
after two weeks of follow-up. Compliance was defined as intake of an average of at least 
four of the prescribed six tablets of regular paracetamol per day (2660 milligrams in total) 
during the first two weeks after enrolment. Exploratory analyses using alternative time 
points and definitions of compliance were conducted. Mean between-group differences 
in pain intensity on a 0-10 scale using the primary time point and definition of compli-
ance were not clinically relevant (propensity weighted CACE 0.07 (-0.37, 0.50) p = 0.76; 
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joint modelling CACE 0.23 (-0.16, 0.62) p = 0.24; ITT 0.11 (-0.20, 0.42) p = 0.49; PP 0.29 
(-0.07, 0.65) p = 0.12); results for secondary outcomes and for exploratory analyses were 
similar. The conclusion of this study was that paracetamol is ineffective for acute low 
back pain, even for patients who comply with treatment.
In the third and final reanalysis of the PACE data, the association between reporting 
AEs and the outcomes of acute LBP was investigated. The results of this project were pre-
sented in chapter 7. Reporting any AE was strongly associated with the use of medicines 
for a health problem other than LBP (odds ratio (95% CI) 1.42 (1.07-1.88)). Reporting any 
AE was not associated with less favorable outcomes for LBP intensity, physical function-
ing, HRQoL or time until recovery (respective coefficients 0.00 (-0.07-0.07), 0.02 (-0.05-
0.10), -0.44 (-1.08-0.20), -0.54 (-1.37-0.29) and HR 1.09 (0.94-1.26)). Due to the very low 
number of serious AEs (death or hospitalization) there was insufficient information to 
investigate the association between reporting these AEs and baseline characteristics or 
the association with outcomes of LBP. In the PACE trial, reporting adverse events after 
using paracetamol or placebo was associated with the use of medicines for other health 
problems, but not with (unfavorable) outcomes of LBP.
In chapter 8, the findings in this thesis were summarized and discussed in terms of 
methodological limitations. Moreover, the implications of the findings for clinical practice 
and for future research were debated.
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Het doel van dit proefschrift was 1) om de overeenkomsten en verschillen tussen aan-
bevelingen voor de medicamenteuze behandeling van lage rugpijn uit recente behan-
delrichtlijnen te vergelijken; 2) om te onderzoeken of de resultaten en conclusies van de 
‘Paracetamol for Acute Low Back Pain’ (PACE) trial reproduceerbaar zijn; 3) om het effect 
van paracetamol op de uitkomsten van acute aspecifieke lage rugpijn te onderzoeken 
onder therapietrouwe deelnemers van de PACE trial; en 4) om te onderzoeken of er een 
associatie is tussen het rapporteren van bijwerkingen en de uitkomsten van acute lage 
rugpijn.
In hoofdstuk 2 werd een systematisch literatuuronderzoek gepresenteerd naar de 
aanbevelingen voor de conservatieve farmacologische behandeling van lage rugpijn uit 
recente behandelrichtlijnen. Deze richtlijnen werden vergeleken met elkaar en met het 
beste beschikbare bewijs over de effectiviteit van medicijnen. Acht recente nationale 
behandelrichtlijnen werden geïncludeerd in deze review (uit Australië, België, Canada, 
Denemarken, Duitsland, Groot Brittannië, Nederland en de Verenigde Staten (VS)). Alle 
richtlijnen stappen af van het adviseren van medicamenteuze behandeling vanwege de 
beperkte effectiviteit en het risico op bijwerkingen. Niet-steroïde anti-inflammatoire 
geneesmiddelen (NSAIDs) hebben paracetamol vervangen als de eerste keus pijnstillers 
in veel richtlijnen. Opioïden worden in alle richtlijnen beschouwd als een laatste redmid-
del, maar desondanks is het aantal voorschriften van deze medicijnen in de laatste jaren 
sterk gestegen. Er is slechts beperkt bewijs voor de effectiviteit van antidepressiva en 
anti-epileptica bij de behandeling van chronische lage rugpijn. Spierverslappers zijn een 
van de medicijnen van eerste keus in de VS, maar zijn niet uitgebreid beschikbaar in de 
meeste andere landen. Aangezien farmacologische behandelingen van lage rugpijn in het 
beste geval maar kleine tot gemiddeld grote effecten hebben, terwijl het gebruik ervan 
wel gepaard gaat met een risico op bijwerkingen, zouden nieuwe versies van behandel-
richtlijnen hun focus moeten verleggen van pijn naar functie en van farmacotherapie 
naar niet-farmacologische behandelopties.
De PACE trial, die werd gepubliceerd door Williams en collega’s in 2014, was de eerste 
grote gerandomiseerde gecontroleerde trial (RCT) die de effectiviteit van paracetamol 
voor acute lage rugpijn onderzocht. Een onderzoeksprotocol voor een nieuwe RCT als 
opvolger van PACE werd gepresenteerd in hoofdstuk 3; deze nieuwe studie heette de 
‘PACE Plus trial’. Deze trial had als doel om de effectiviteit van 4 weken behandeling met 
paracetamol, diclofenac en placebo voor de behandeling van patiënten met acute lage 
rugpijn te onderzoeken en om de toegevoegde waarde van paracetamol, diclofenac en 
placebo te onderzoeken vergeleken met alleen geruststelling. Patiënten met een leeftijd 
tussen de 18 en 60 jaar die zich in de huisartspraktijk presenteerden met acute lage rug-
pijn werden geïncludeerd in de studie, en vervolgens gerandomiseerd naar vier behan-
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delgroepen: 1) alleen advies (conform de standaardbehandeling uit de NHG-standaard); 
2) advies en paracetamol; 3) advies en diclofenac; en 4) advies en placebo. De primaire 
uitkomstmaat was pijnintensiteit, gemeten met een numerieke schaal (van 0 tot 10). Se-
cundaire uitkomstmaten waren fysiek functioneren, gezondheidsgerelateerde kwaliteit 
van leven, ervaren herstel, therapietrouw, kosten, bijwerkingen, patiënttevredenheid, 
slaapkwaliteit, co-interventies en adequaatheid van blindering.
Doordat onvoldoende patiënten geworven konden worden, moest de PACE Plus trial 
prematuur beëindigd worden binnen zes maanden na de start van het onderzoek. In 
hoofdstuk 4 werden de redenen voor het staken van PACE Plus geëxploreerd. Huisart-
sen uit 36 deelnemende praktijken ontvingen een vragenlijst die bestond uit slechts 
één vraag; hierin werden zij gevraagd om de drie redenen te geven die naar hun 
idee het meest hadden bijgedragen aan het mislukken van de werving van patiënten. 
Huisartsen van 33 van de 36 deelnemende praktijken (92%) stuurden een antwoord; in 
totaal werden 81 factoren gerapporteerd. Deze factoren werden gecategoriseerd naar 
patiëntfactoren (26 van de 81 factoren, 32%), huisartsfactoren (39 van de 81 factoren, 
48%) en onderzoeksfactoren (16 van de 81 factoren, 20%). De werving van patiënten 
in PACE Plus is mogelijk gefaald door een inefficiënte procedure voor de distributie van 
studiemedicatie, de werving van incidente cases in plaats van prevalente cases, een te 
complex onderzoeksdesign, zelfredzaamheid van patiënten met lage rugpijn, andere 
verwachtingen van patiënten dan deelname aan klinisch onderzoek en tijdgebrek van 
deelnemende huisartsen. Substantiële verschillen in studiedesign zouden kunnen 
verklaren waarom de Australische voorloper PACE wel succesvol patiënten kon werven. 
Hoewel de PACE Plus studie gestaakt is, blijven de onderzoeksvragen van deze studie 
relevant maar onbeantwoord.
Er werden drie secundaire analyses uitgevoerd van data die in de PACE trial was ver-
zameld. De reproduceerbaarheid van de oorspronkelijke conclusies van PACE werden 
onderzocht in hoofdstuk 5. Een onafhankelijk onderzoeksteam maakte gebruik van het 
analyseplan van de PACE Plus trial om de PACE trial opnieuw te analyseren. Deze repro-
ductie analyses toonden aan dat er geen effect was van behandeling met paracetamol 
op pijnintensiteit en de betrouwbaarheidsintervallen sloten klinisch relevante effecten 
uit (coëfficiënt voor reguliere paracetamol versus placebo 0.00 (-0.02 – 0.01, p = 0.92)). 
Vergelijkbare resultaten werden gevonden voor alle secundaire uitkomsten (fysiek func-
tioneren, gezondheidsgerelateerde kwaliteit van leven, slaapkwaliteit en tijd tot herstel). 
Dit wees erop dat de conclusies van de PACE trial reproduceerbaar zijn, zelfs als een 
andere statistische benadering gebruikt wordt. Dit versterkt het idee dat de behandeling 
van patiënten met acute lage rugpijn zich zou moeten richten op het verstrekken van 
advies en geruststelling aan patiënten, zonder de toevoeging van paracetamol.
Een andere secundaire analyse werd gepresenteerd in hoofdstuk 6. Deze studie 
had als doel om het effect van paracetamol op de uitkomsten van acute lage rugpijn 
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te onderzoeken bij deelnemers van de PACE trial die zich hielden aan het geadviseerde 
medicatieschema. Met behulp van individuele deelnemersdata van de PACE trial werden 
Complier Average Causal Effect (CACE), Intention-to-treat (ITT) en Per Protocol (PP) 
analyses uitgevoerd voor pijnintensiteit (primaire uitkomstmaat) en fysiek en dagelijks 
functioneren en ervaren verandering van symptomen (secundaire uitkomsten) na twee 
weken follow-up. Therapietrouw was gedefinieerd als het innemen van gemiddeld min-
stens vier van de voorgeschreven zes tabletten reguliere paracetamol per dag (een totaal 
van 2660 milligram) gedurende de eerste twee weken na randomisatie. Tevens werden 
verkennende analyses met alternatieve tijdspunten en definities voor therapietrouw 
uitgevoerd. De gemiddelde verschillen tussen de groepen in pijnintensiteit op een schaal 
van 0 tot 10 waren niet klinisch relevant op het primaire tijdspunt en bij de primaire 
definitie van therapietrouw (propensity-gewogen CACE 0.07 (-0.37, 0.50) p = 0.76; joint 
modelling CACE 0.23 (-0.16, 0.62) p = 0.24; ITT 0.11 (-0.20, 0.42) p = 0.49; PP 0.29 (-0.07, 
0.65) p = 0.12); resultaten voor secundaire uitkomsten en voor verkennende analyses 
waren vergelijkbaar. De conclusie van deze studie was dat paracetamol ineffectief is voor 
acute lage rugpijn, zelfs voor therapietrouwe patiënten.
In de derde en laatste heranalyse van de PACE data werd de associatie tussen het 
rapporteren van bijwerkingen en de uitkomsten van acute lage rugpijn onderzocht. 
De resultaten van dit project werden gepresenteerd in hoofdstuk 7. Het rapporteren 
van bijwerkingen was sterk geassocieerd met het gebruik van medicijnen voor andere 
gezondheidsproblemen dan rugpijn (odds ratio (95% betrouwbaarheidsinterval) 1.42 
(1.07-1.88)). Er was geen associatie tussen het rapporteren van bijwerkingen en de 
uitkomsten pijnintensiteit, fysiek functioneren, gezondheidsgerelateerde kwaliteit van 
leven of tijd tot herstel (respectievelijke coëfficiënten 0.00 (-0.07-0.07), 0.02 (-0.05-0.10), 
-0.44 (-1.08-0.20), -0.54 (-1.37-0.29) en hazard ratio 1.09 (0.94-1.26)). Vanwege een zeer 
klein aantal ernstige bijwerkingen (met hospitalisatie als gevolg) was er onvoldoende 
informatie beschikbaar om de associatie tussen het rapporteren van deze ernstige bij-
werkingen en baseline karakteristieken of tussen het rapporteren van deze bijwerkingen 
en de uitkomsten van rugpijn te onderzoeken. In de PACE trial was het rapporteren van 
bijwerkingen na inname van paracetamol of placebo dus geassocieerd met het gebruik 
van medicijnen voor andere gezondheidsproblemen, maar niet met (ongunstige) uitkom-
sten van lage rugpijn.
In hoofdstuk 8 werden de bevindingen van dit proefschrift samengevat en bediscus-
sieerd in het kader van methodologische beperkingen. Tevens werden de implicaties van 
deze bevindingen voor de klinische praktijk en voor toekomstig onderzoek besproken.
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